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Abstract
Metastasis, the leading cause of mortality in cancer patients, is the dissemination 
of cancer cells from the primary tumour and spread to the distant sites of the body. This 
is a complex process during which tumour cells need to overcome several natural 
barriers to gain entry into the bloodstream and thus allow formation of secondary 
tumour in distant location. In the last two decades, much effort has been focused on 
showing that tumour cells use specialized actin-based membrane protrusions termed 
invadopodia to perform matrix degradation. Invadopodia gain their protrusive capacity 
combining the mechanical force of actin polymerization with the chemical activity of 
matrix degradation. As such, invadopodia are F-actin-rich structures enriched in 
integrins, tyrosine kinases signalling machinery, soluble and membrane proteases, 
including matrix metalloproteases (MMPs), and actin-associated proteins. How all these 
components are specifically recruited to the ECM degradation sites has not been fully 
clarified yet.
An emerging model describes invadopodia as dynamic cellular platforms where 
the signalling, membrane trafficking and cytoskeleton remodelling converge upstream 
of ECM degradation at spatially confined cholesterol-rich membrane compartments. 
Despite the field of invadopodia biogenesis and function is still a very recent, it is 
witnessing an increasing interest and an increasing number of molecular players have 
been identified in the last two decades. Although the existence of the invadopodia-like 
structures in vivo settings still needs to be determined, invadopodia represent powerful 
experimental paradigm to study the tight integration between the signalling, the
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membrane trafficking and cytoskeleton remodelling upstream of ECM degradation, the 
rate-limiting step in cell invasion, and might provide better understanding of cancer cell 
invasion and metastasis.
In order to investigate the cholesterol-rich lipid raft feature of invadopodia, I 
followed three lines. First, I showed that inhibition of cholesterol formation at 
penultimate step of its biosynthesis, and subsequent accumulation of desmosterol, 
blocks formation and function of invadopodia, thus demonstrating that the central role 
of cholesterol is connected to its presence in functional lipid rafts. In the second 
approach, I found that the SFKs inhibitory kinase Csk is a negative regulator of 
invadopodia-mediated ECM degradation and its role depends on the localization in the 
cholesterol-rich lipid rafts. Finally, I demonstrated that free cholesterol-dependent 
ARF6-associated recycling pathway might be involved in the trafficking to 
invadopodia, while the ARF6-pathway constituents are localized at ECM degradation 
sites and ARF6-specific cargo CD 147 is recycled to invadopodia.
Taken together, my findings provide novel insight towards the elucidation of 
invadopodia as specialized cholesterol-dependent membrane domains where signal 
transduction and membrane trafficking events might be temporally and spatially 
confined.
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CHAPTER 1: Introduction
1.1 Tumour cell invasion
Cancer is not one but many diseases that arise from a host of different genetic 
causes. Generally speaking, the neoplastic progression requires the acquisition of 
genetic mutations that lead either to loss of tumour suppressors or activation of 
oncogenes. Broadly, tumours are classified based on the tissue of origin and 
subsequently by the molecular markers or genetic abnormalities they possess. 
Notwithstanding their heterogeneity, it is accepted that cells must gain several 
properties to become malignant. Hanahan and Weinberg (2011) provided in their 
updated influential review a logical framework to analyze the complexity of malignant 
transformation. The seminal distinctive capabilities of cancer cells that lead to 
tumourigenesis is primarily characterized by genomic instability leading to aberrant 
proliferation signalling, insensitivity to growth suppressors, resistance to apoptosis, 
neoangiogenesis, limitless replication potential, reprogramming of cell energy 
metabolism, evasion of the immune system response, and tissue invasion and metastasis 
(Hanahan and Weinberg, 2011).
Metastasis, a leading cause of mortality in cancer patients, is a common 
phenomenon of malignant tumours, which makes it an excellent target for therapeutic 
intervention. The metastatic process is a multistage one whereby cancer cells escape 
from the primary tumour and break through basement membrane to invade local tissue 
and vessels to eventually colonize distant sites to form a secondary tumour. It is
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believed that the ability of tumour cells to cross the tissue barriers is facilitated by 
forming specific F-actin rich invasive structures that, in vitro, are visualised and studied 
as invadopodia (“invasive feet”), that focalize the degradation of the surrounding matrix 
and serves as platforms where the cytoskeletal, cell signalling, membrane trafficking 
and proteolytic pathways are integrated towards a defined biological function.
15
1.2 Invadopodia: The invasion machinery of cancer cells
As aforementioned, breaking through the ECM barrier is essential for the 
invasion of tumour cells and proteolytic degradation associated with migratory 
phenotype is a common feature of tumour cells. Hence, understanding this process is of 
a particular importance for targeting the therapeutic intervention. Invadopodia, the F- 
actin rich structures that localize the degradative capability of tumour cells, provide an 
excellent platform to understand the mechanism and biology of cancer cell invasion. In 
the last two decades, invadopodia witnessed an increasing interest and the accumulating 
data have shed light on the molecular complement and on the molecular mechanism 
governing the formation and function of invadopodia, as it is discussed in a number of 
recent reviews focusing on diverse aspects of invadopodia biology, such as signalling to 
invadopodia (Boateng and Huttenlocher, 2012; Destaing et al., 2011; Hoshino et al., 
2013; Sibony-Benyamini and Gill-Hen, 2012), pathological role of invadopodia (Eckert 
and Yan, 2011; Stylli et al., 2008; Yamaguchi, 2012), actin polymerization and 
remodelling (Albiges-Rizo et al., 2009), and trafficking to invadopodia (Caldieri and 
Buccione, 2009; Frittoli et al., 2010).
1.2.1 Definition of invadopodia
Invadopodia are plasma membrane structures with the ability to degrade 
extracellular matrix, first described in the Chen’s laboratory as rosette-shaped adhesion
16
sites formed by Rous sarcoma virus-transformed chicken embryonic fibroblasts (Chen, 
1989). They are stable actin-rich protrusions emanating from the ventral surface of 
invasive tumour or transformed cells. Importantly, these structures can degrade 
extracellular matrix (ECM) by modulating the focused release and activation of 
proteases, when plated on ECM substrate, such as gelatine, collagen I, collagen IV, 
fibronectin or laminin (Kelly et al., 1994).
Invadopodia are mainly visualized on a thin layer of ECM covered coverglasses, 
on which can be seen as roundish actin-rich structures that are associated with sites of 
matrix degradation, are not confined to the cell periphery and contain actin-related 
proteins, such as cortactin, and/or phosphotyrosines (Baldassarre et al., 2006; Bowden 
et al., 2006).
In point of fact, the ability of tumour cells to form invadopodia often correlates 
with their metastatic and invasive potential. For instance, invadopodia formation has 
been confirmed in primary tumour cells obtained from the patients with invasive head 
and neck squamous cell carcinoma (HNSCC) (Clark et al., 2007), glioblastoma (Stylli 
et al., 2008) and bladder cancer (Yamamoto et al., 2011).
1.2.2 Podosomes or invadopodia?
Due to the functional and structural similarities, the terms podosomes and 
invadopodia have been initially used interchangeably. A defining feature of both 
invadopodia and podosomes is indeed the coordination between the attachment to ECM 
and pericellular proteolysis activity, supported by the presence of a range of proteases in
17
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Fig. 1.1. Identification of invadopodia. Double staining of 
A375MM melanoma cells grown on FITC (green) or rhodamine 
(red)-conjugated gelatin and then fixed and stained for: (a) actin; 
(b) cortactin; (c) dynamin. Invadopodia match underlying areas of 
degradation (black patches). A merged image is also shown. Scale 
bar 10 pm.
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both structures. Consequently, they share many common molecular constituent and 
activating pathways. Despite the numerous similarities between the structures, there are 
some notable differences and clear distinctions have been made based on the cell origin, 
lifetime and morphological classification. Podosomes are generally considered as more 
typical of differentiated cell lines, such as osteoclasts, macrophages, vascular 
endothelial and smooth muscle cells, whereas invadopodia are formed by transformed 
or tumour cells as a result of neoplastic aberrations. Podosomes consist of a densely 
packed actin core surrounded by a ring of components commonly found in focal 
adhesion structures (Gimona et al., 2008; Linder, 2009; Linder, 2007). Podosomes are 
dynamic, rapidly turning-over (2-12 minutes), relatively small (1 pm in diameter and x 
0.4 pm in height), dot-like structures organised in rings and/or distributed at the leading 
edge, typically present in large numbers (20-100). At variance, invadopodia are 
persistent (up to 3 hours), large (up to 8x5 pm), irregularly shaped actin-rich formations, 
which tend to be confined to the central area of cells, and are less numerous than 
podosomes (1-10/cell). As a consequence of invadopodia persistence, the pattern of 
degradation mediated by invadopodia is deeper and more focused compared to the 
shallow, widespread degradation by podosomes.
Interestingly however, observation by live-cell total internal reflection 
fluorescence (TIRF) microscopy revealed fundamental differences in membrane 
dynamics of both structures. This study suggests a highly dynamic nature of the 
invadopodial structure where the ruffling and undulation of the invadopodial membrane 
is accompanied by formation of filament-like invadopodia. On the contrary, parallel 
TIRF microscopy studies of macrophage podosomes compared to invadopodia
19
established that the podosome membrane does not form any filament-like membrane 
extensions or protrusions in cells on the two-dimensional (2D) ECM (Artym et al., 
2010).
In addition, comparison of the podosome consensus list of proteins with 
published invadopodia proteome revealed extensive overlap, which seems to consist 
mainly of metabolic proteins (Attanasio et al., 2011; Cervero et al., 2012).
1.2.3 Invadopodial structure
Early electron microscopy studies of transformed fibroblast invading thin 2D 
matrices suggested that invadopodia are regions of ventral plasma membrane extending 
into the underlying ECM, with a central electron dense cytoplasmic core or with the 
central core extending into long filaments (Chen, 1989). Later observation on a breast 
cancer-derived cell line grown on gelatine cross-linked beads confirmed this concept of 
invadopodia (Bowden et al., 1999). Further detailed ultra-structural analysis of 
melanoma cells using a correlative confocal light electron microscopy (CLEM) 
approach shows multiple filament-like invadopodia to be a part of an invasion 
superstructure of profound ventral cell membrane invaginations that measured in 
average 8 pm in width and 2 pm in depth. From within, many surface protrusions 
originated, with diameters ranging from hundreds of nanometres to a few micrometres, 
and 500 nm in length, which sometimes penetrated into the matrix (Baldassarre et al., 
2006). In addition, by the same approach, CLEM, invadopodial invaginations were 
found to be in close relationship with Golgi complex (Baldassarre et al., 2003).
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Golgi Complex
Invadopodia
Extracellular matrix
Fig. 1.2. Schematic diagram of invadopodia organisation. This 
drawing is based on correlative light-electron microscopy 
reconstructions from serial sections of A375MM melanoma cells 
(Baldassarre et al., 2003). Invadopodial protrusions originate from 
profound invaginations of the ventral surface of the plasma 
membrane; within the area delimited by the large invagination, 
large fragments of gelatin can often be seen. Also shown are the 
spatial relationships with the nucleus and the Golgi complex.
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More recently, transmission electron microscopy has been employed to analyze 
the ultra-structural organization of invadopodia formed in the chemo-invasion assay, 
where invadopodia are allowed to grow through membrane pores, thus forming longer 
protrusions (Schoumacher et al., 2010). In transmission electrographs, the randomly 
arranged actin bundles have been identified at the very tip or at the sides of invadopodia. 
Unexpectedly, the presence of intermediate filaments and microtubules has been 
confirmed in this long mature invadopodia. This is a first evidence of the presence of 
such cytoskeletal elements at invadopodia. Neither intermediate filaments nor 
microtubules are required for invadopodial formation, but they appear to be essential for 
the elongation of invadopodia. Typically, one to two microtubules were embedded in 
the meshwork of intermediate filaments at the core of long mature invadopodia. Finally, 
many vesicles were found within protrusions, implying active traffic at mature 
invadopodia (Schoumacher et al., 2010).
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Fig. 1.3. Electron micrographs of mature invadopodia. Image A 
shows mature invadopodia in MDA-MB-231 on Matrigel-coated 
transwell. The same image (A’) is color coded to distinguish 
cytoskeleton network: orange-microtubules, blue-intermediate
filaments, and actin in yellow.. Images on the right are a higher 
magnification of the corresponding boxed regions in A (red-base; 
green-tip of invadopodia.) c, cell; f, filter; m, Matrigel. Bars: (A 
and A [left]) 0.5 pm; (A, right) 0.25 pm. Image taken from 
Schoumacher et al., (2010).
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1.2.4 Invadopodial components
A majority of studies has used immunofluorescence and fluorescent protein- 
tagged proteins to image the localization of specific proteins at invadopodia. This 
approach together with siRNA-mediated interference of definite proteins has led to 
identification of an expanding list of proteins involved in invadopodia biogenesis, 
including integrins, proteins of canonical signalling pathways, soluble and membrane 
bound proteases, actin and actin-associated proteins.
More recently, a proteomic study conducted on invadopodia-enriched cell 
fractions came up with a significant number of new invadopodia-associated proteins, 
provided a quantitative analysis of protein levels by Difference Gel Electrophoresis 
(DIGE) on invasive human melanoma cell line A375MM. Almost 60 new proteins were 
identified that could be divided into different functional classes: a) protein synthesis, 
degradation and folding; b) glycolytic and associated metabolic proteins; c) cytoskeletal 
components and membrane associated proteins (Attanasio et al., 2011).
1.2.5 Regulation of invadopodia formation
Beside the description of molecular components of invadopodia, much attention 
is centered to the comprehension of the regulation of invadopodia formation and their 
initiation, which might ultimately aid comprehension of factors that lead to metastatic 
behaviour. In addition to the adhesion, the regulation of invadopodia formation has been 
connected to other stimulants, including growth factors, and substrate stiffness and
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membrane curvature may also play an important role in the invadopodia induction, as 
discussed briefly hereafter.
1.2.5.1 Role of ECM and adhesion protein signalling
Adhesion signalling, especially by integrins, is likely to be a critical regulatory 
event in the formation and function of invadopodia. Integrins belong to the family of 
heterodimeric transmembrane adhesion proteins consisting of 18 a and 8 p subunits that 
can make up 24 distinct non-covalently linked heterodimers with specific tissue 
distribution. Various combinations of a and p subunits endow integrins with specific 
ligand binding characteristics. Due to their ability to switch from low to high affinity 
conformation, they are likely to sense physicochemical properties of the substrate. 
Though their primary function is to mediate cell-cell and cell-ECM adhesion, 
respectively, integrins play also an important role in signal transduction and cytoskeletal 
reorganization. Integrins directly interact with ECM components and transmit the 
extracellular information in the cell (outside-in signalling) as well as other way round 
(inside-out signalling).
The role of integrins at invadopodia is incompletely understood. The 
engagement of cell surface integrins by substrate components is the thought to be the 
trigger of invadopodia formation (Mueller et al., 1999; Nakahara et al., 1998; Nakahara 
et al., 1996). To date, which integrin(s) subunit(s) is responsible for invadopodia 
regulation remains unclear. The specific integrin combinations that, when engaged, lead 
to invadopodia formation, might be cell-type dependent. For example, invadopodia still
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form in the absence of P3 integrin but they are inhibited in case of loss of pi integrin 
(Beaty et al., 2013).
Another line of evidence accounts for pi involvement in the invadopodia- 
dependent degradation process. Deregulation of pi has been associated with tumour 
aggressiveness in number of models, such as pancreatic, skin, breast and ovarian cancer. 
In melanoma cells, activation of a6pl promoted SFK-dependent phosphorylation of 
pl90RhoGAP, which resulted in Rho family GTPases-dependent rearrangements of 
actin cytoskeleton and eventually, invadopodia formation (Nakahara et al., 1998). Beaty 
et al. (2013) showed that pi is not required for invadopodia precursor formation upon 
epidermal growth factor (EGF) stimulation; however, it is indispensable for formation 
of mature, fully active invadopodia (Beaty et al., 2013).
Involvement of integrins in the degradation process might imply a direct effect 
on the protease secretion. For instance, collagen-induced a3pi association with the 
serine protease seprase was shown to drive the degradative activity of this gelatinolytic 
enzyme specifically at the tip of invadopodia (Artym et al., 2002). An inhibitory anti-pl 
integrin antibody prevented the association between urokinase-type plasminogen 
activator receptor (uPAR) and seprase at invadopodia, suggesting a fundamental role for 
pi in the organisation and targeting of proteases at sites of ECM degradation (Artym et 
al., 2002). Moreover, integrins cooperated with membrane-type 1 matrix 
metalloprotease (MT1-MMP) to localize and enhance proteolysis through the activation 
of matrix metalloproteinase-2 (MMP2) (Deryugina et al., 2002). Recently, a formation 
of integrin and integrin linked kinase (ILK)-dependent adhesion rings has been 
described. The adhesion rings formed around invadopodia shortly after their formation
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and correlated positively with invadopodia activity. Strikingly, prevention of formation 
of the adhesion rings reduced both recruitment of IQ motif containing GTPase 
activating protein (IQGAP) and MT1-MMP accumulation at invadopodia site, probably 
through the impaired capture of MTl-MMP-containing vesicles (Branch et al., 2012). 
Similarly, it had been shown in another study that actin core assembled before the 
integrin-containing adhesion ring, and actin disruption was a prerequisite for 
invadopodia disassembly (Badowski et al., 2008).
In conclusion, it has not been fully elucidated how integrins regulate 
invadopodia biogenesis. The latest evidence suggest that rather than inducing 
invadopodia formation, integrins act lately during invadopodia maturation by activating 
downstream signalling events and serving as docking sites for proteases.
1.2.5.2 Role of growth factors
Many growth factors have been shown to promote the formation of both 
invadopodia and podosomes (Hoshino et al., 2013). Here, I will simply mention those 
known to induce the formation of invadopodia in cancer cells. A well-characterized and 
studied inducer of invadopodia is epidermal growth factor (EGF) (Yamaguchi et al., 
2005). Subsequent studies showed that the basic helix-loop-helix (bHLH) transcription 
factor TWIST, an inducer of epithelial-mesenchymal transition (EMT), promoted 
invadopodia formation by upregulation of platelet-derived factor receptor a (PDGFRa) 
(Eckert et al., 2011). Moreover, knockdown of TWIST1 blocked the ability of TGFp to 
induce invadopodia formation via PDGFRa. The implicated role of TGFp is also
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supported by a study showing that stimulation by TGFp led to phosphorylation of 
hydrogen peroxide-inducible clone 5 protein (Hic5), required for invadopodia formation 
and invasion (Pignatelli et al., 2012).
1.2.5.3 Role of matrix stiffness
Matrix stiffness due to collagen deposition is known to play a role in the 
propensity of metastatic behaviour of tumour cells (reviewed in Boyd et al., 2005). Still, 
both the occurrence and relevance of mechanosensing at invadopodia remain to be fully 
understood. In a first report addressing this issue, Alexander et al. (2008) showed that 
breast cancer cells increased both the number and activity of invadopodia when plated 
on increasing concentrations of gelatine without altering the protein composition of the 
substrate. This study suggested that regulation of invadopodia formation by substrate 
rigidity might occur via a myosin II-focal adhesion kinase (FAK)/Crk-associated 
substrate (Cas) axis, which acts as a mechanosensing machine (Alexander et al., 2008).
1.2.5.4 Role of membrane curvature
Invadopodia are protrusive structures formed through mechanism a coupling 
actin polymerization with membrane curvature (Albiges-Rizo et al., 2009), therefore 
continuous membrane remodelling is required to allow the growth of invadopodia. The 
Bin-Amphiphysin-Rsv domain (BAR) and F-BAR proteins are involved in the 
formation of positive curvature of the membrane, i.e. inward bending of the membrane.
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Recently, the F-BAR protein, Cdc42 interacting protein 4 (CIP4), has been show to play 
a role at invadopodia both as means to promote membrane curvature and as a scaffold 
protein to promote actin polymerization (Hu et al., 2011; Pichot et al., 2010).
Expression of CIP4 is elevated in aggressive breast cancer and appears to confer 
an invasive phenotype by promoting cell migration and invadopodia formation and 
function. It has been demonstrated that the action of CIP4 is based on Src-dependent 
phosphorylation of N-WASP that initiates actin polymerization. Since CIP4 serves as a 
scaffold for Cdc42, Src and N-WASP, to target actin polymerization to the sites of 
membrane curvature, which could be the very case of invadopodia protrusions (Pichot 
et al., 2010). Shortly thereafter, another study on CIP4 was published, describing its role 
in the contrast as a negative regulator of invadopodia formation by promoting MT1- 
MMP internalization (Hu et al., 2011). Although both studies were executed in the same 
cell line, breast cancer-derived MDA-MB-231 cell line, methodological differences 
might account for the varied results. The main difference was in the use of acute, 
siRNA-mediated knock-down of CIP4 (Pichot et al., 2010) or stable, shRNA-mediated 
knock-down of CIP4 (Hu et al., 2011).
Similarly, expression of F-BAR domain containing adaptor protein transducer of 
Cdc42-dependent actin assembly-1 (Toca 1) correlates with malignant phenotype of 
breast cancer cells, and Toca 1 associates with a number of actin regulatory proteins 
present at invadopodia. Toca 1 colocalized with actin-rich cortactin core of 
invadopodial protrusion and promoted invadopodia formation, most likely due to 
promotion of actin branching (Chander et al., 2013).
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1.2.6 Signalling to invadopodia
Following the detection of signal inputs such as cross-linked integrins or growth 
factors, series of signalling pathways are activated that induce the actin polymerization 
and other events required for invadopodia initiation and formation. Recent research has 
highlighted the importance of a number of signalling elements, including Src family 
kinases (SFKs), Abelson kinases (Abl), protein kinase C (PKC) and some members of 
Ras superfamily of small GTPases, as I will discuss in this section.
1.2.6.1 Tyrosine phosphorylation at invadopodia
Tyrosine phosphorylation is a convenient, reversible switch to regulate cellular 
processes by the addition of negatively charged phosphate groups to the specific 
tyrosine residues. As a result, the chemical and functional properties of proteins are 
altered substantially, which includes allosteric modification, formation of a new protein 
complex, activation or deactivation, or a release from an inhibitory complex.
Invadopodia were historically described as a major cytoskeleton reorganization 
induced by the expression of oncogene v-Src (Chen, 1989); high levels of tyrosine 
phosphorylation and dependence on Src activity were subsequently and specifically 
associated with such structures (Mueller et al., 1992). The non-receptor Src family of 
tyrosine kinases (SFK) comprises nine closely related members that share three 
important structural domains, designated as Src Homology (SH) domains: a catalytic 
domain SHI preceded by non-catalytic SH2 and SH3 domains. The SH2 domain is
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responsible for binding to phosphotyrosine rich protein regions, whereas SH3 domain 
binds polyproline sequences. Localization to specific cell membranes is regulated by N- 
terminal “unique” domain, highly diverse among family members. Additionally, SFK 
activity is controlled through activatory phosphorylation in the A-loop and the C- 
terminal autoinhibitory phosphorylation site (Y527 in Src) (Ingley, 2008; Thomas and 
Brugge, 1997). Src is indispensable for invadopodia formation and function, and the 
degree of tyrosine phosphorylation positively correlates with invadopodia activity, as 
has been demonstrated through several different approaches. Initially, Bowden et al. 
(2006) showed that the majority of the tyrosine phosphorylated proteins resides in the 
invadopodia-enriched fraction and the cell treatment with phosphatase inhibitor 
orthovanadate to prevent dephosphorylation resulted in a higher degree of matrix 
degradation (Bowden et al., 2006). Several studies have confirmed that cell treatment 
with SFK inhibitors blocks the formation of invadopodia and consequently of matrix 
degradation; also, transfection with kinase-active or kinase- inactive Src mutants, 
increased or decreased the levels of ECM degradation, respectively, as compared to the 
wild type Src-expressing cells (Bowden et al., 2006; Hauck et al., 2002).
Another non-receptor tyrosine kinase of the Abelson (Abl) family of tyrosine 
kinases has recently been brought into the picture. Abl family includes Abl and Abl- 
related gene (Arg) kinases, both of which are the only known tyrosine kinases to 
interact with the cytoskeleton (reviewed in Colicelli, 2010). Src phosphorylates and 
activates Abl and Arg upon the signalling input of growth factors such as EGF and 
PDGF. The subsequent activation led to direct phosphorylation of cortactin, responsible 
for maturation of invadopodia in melanoma and breast cancer cell lines (Mader et al.,
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2011; Smith-Pearson et al., 2010). However, the effect of Abl kinases might be more 
complex, as was reported in a comparative study of MDA-MB-231 (a breast cancer- 
derived cell line widely used for studying of invadopodia biology) and HNS SC (a head 
and neck squamous carcinoma-derived cell line). While in MDA-MB-231 cells 
silencing of Abl kinases prevented invadopodia formation, in HNSSC cells ablation of 
Abl led to promotion of invadopodia formation and associated matrix degradation 
(Hayes et al., 2012). On the contrary, in a study focusing on the role of cortactin, Abl 
was shown not to play a role in the invadopodia formation in another widely used cell 
model A375MM melanoma cells (Ayala et al., 2008). Thus, further research is needed 
to gain insight into the mechanistic of Abl role at invadopodia and cancer cell invasion 
in general.
A central role of SFK in invadopodia regulation is further inferred by the 
relevance of a number of direct SFK substrates involved in invadopodia function. 
Among the most relevant is cortactin, which I will be discussing in section 1.2.7.3.
Paxillin is a multi-domain adaptor protein that localizes to the extracellular 
matrix contacts. It consists of multiple protein-binding modules, many of which are 
under the control of phosphorylation, and thus interacts with numerous regulatory and 
structural proteins to control cell adhesion, cytoskeletal remodelling and gene 
expression in cell migration, invasion and survival. In particular, paxillin emerged as an 
important regulator of the spatiotemporal action of Rho GTPases, by recruiting a 
number of their accessory proteins (reviewed in Deakin and Turner, 2008). 
Phosphorylation of paxillin at tyrosines 31 and 118 aids a formation of a complex with 
PKC and cortactin to increase invasiveness of the cell lines tested (Bowden et al., 1999).
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Moreover, expression of phosphorylation deficient mutants resulted in impaired 
disassembly of invadopodia actin core and consequent formation of thick, less 
degrading invadopodia with small lumens (Badowski et al., 2008).
The Src substrate tyrosine-kinase substrate (Tks) 5, formerly known as FISH, is 
required for invadopodia formation and invasive behaviour of a number of cancer cell 
lines (Abram et al., 2003; Seals et al., 2005). Of particular interest is observation that 
Tks5 is expressed exclusively in invasive cancer cells, but not in their non-invasive 
counterparts (reviewed in Courtneidge, 2012). Tks5 is a scaffolding protein featuring 
lipid-binding Phox (PX) domain followed by five SH3 domains. Recently discovered 
Tks5-related protein Tks4, that shares the similar domain architecture with Tks5 but 
missing one SH3 domain, has been found to be tyrosine phosphorylated and 
predominantly localized at invadopodia-like structures in Src-transformed fibroblasts; in 
addition, Tks4 knockdown inhibited ECM degradation. Interestingly, Tks 4 and 5 do 
not appear to have overlapping functions as ECM degradation was not rescued by over­
expression of Tks5, probably due to non-redundant role of Tks4 in the MT1-MMP 
recruitment to invadopodia (Buschman et al., 2009). The involvement of Tks proteins at 
invadopodia is not fully elucidated but the emerging knowledge is pointing to many 
aspects of invadopodia biology. Invadopodia formation is initiated at membranes sites 
rich in PtdIns(3,4)P2 (Oikawa et al., 2008). Indeed, the lipid binding PX domain is 
essential for Tks5 function at invadopodia. Moreover, Tks5 binds and modulates the 
actin polymerization regulators N-WASP (Oikawa et al., 2008) and Nckl (Stylli et al., 
2009). Both Tks5 and Tks4 protein associates with members of the A Disintegrin And 
Metalloproteinase (ADAM) family of proteases, namely ADAMs 12,15 and 19,
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involved in processes such as cell adhesion and motility (Abram et al., 2003; Buschman 
et al., 2009). More recently, it has been shown that Tks proteins act as organizers of 
reactive oxygen species (ROS) signalling mediated by NADPH oxidases (Nox) (Diaz et 
al., 2009). In non-phagocytic cells, ROS prove to be mediator of various cellular 
responses and their role at invadopodia formation has been approved (Diaz et al., 2009). 
The effect of ROS on invadopodia has not been elucidated yet, but might involve the 
ROS effect on modulation of activity of SFKs, PKC and small GTPases, combined with 
inhibition of phosphatases and increased secretion of MMPs (reviewed in Giannoni et 
a l, 2010).
The protein caveolin is a major regulator of cholesterol homeostasis at the 
plasma membrane and has been directly implicated in invadopodia biogenesis (Caldieri 
et a l, 2009; Yamaguchi et a l, 2009). Caveolin is also the major component of lipid-raft 
enriched caveolae, flask-shaped invaginations of the plasma membrane implicated in 
endocytosis (Parton et a l, 2006; Williams, 2004). The caveolin family consists of three 
members. Caveolin 1 is a ubiquitous isoform, caveolin 2 is tightly co-expressed with 
caveolin 1 and caveolin 3 replaces caveolin 1 in striated muscle. Caveolin 3 shares 85% 
similarity with caveolin 1 and these two isoforms are mutually interchangeable. The 
caveolins are small proteins (18/24 kDa) with cytosolic C- and N-termini and a central 
domain consisting of 33 hydrophobic amino acids that spans the plasma membrane to 
exhibit an unusual hairpin-like configuration. Caveolins have been approved in 
numerous cell functions, ranging from the regulation of cholesterol homeostasis, 
vesicular transport and regulation of signal transduction (reviewed in Williams and 
Lisanti, 2004). Caveolin has also been directly implicated in tumorigenesis, although,
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depending on cell type and/or tumour stage, it appears to act as a tumour suppressor or 
as an oncogene. This discrepancy might be explained by fact that caveolin has several 
domains with opposing functions (Mercier et al., 2009; Williams, 2004). The caveolin 
scaffolding domain (CSD) between residues 82 and 101 inhibits growth stimulatory 
activity of several signalling proteins, e.g. receptor tyrosine kinases (RTKs) and Src- 
family kinases (SFK), thus acting inhibitory towards growth. Phosphorylation of 
caveolin 1 on tyrosine 14 activates a binding site for SH2-domain containing proteins, 
such as Grb-7 to enhance anchorage-independent growth and EGF-stimulated cell 
migration (Lee et al., 2000), or C-terminal kinase (Csk) to inhibit Src-family kinases 
(SFK). Caveolin 1 phosphorylated on Y14 (pY14-Cavl) also promotes focal adhesion 
disassembly and turnover via the stabilization of focal adhesion kinase (FAK) exchange 
to stimulate migration in breast cancer cells (Goetz et al., 2008). Strikingly, the 
phosphorylation of caveolin 1 on Y14 is an important event in ECM degradation, 
inversely correlating with invadopodia formation (Caldieri et al., 2009).
1.2.6.2 Serine/threonine phosphorylation at invadopodia
Phosphorylation of serine or threonine in specific consensus sites by specific 
kinases is another cellular mechanism to control the activity of proteins. Recently, 
serine/threonine kinases have also been associated with invadopodia biogenesis. 
Extracellular signal regulated protein kinase 1/2 (Erkl/2) is a part of a large signalling 
network of mitogen activated protein (MAP) kinases, which regulate a number of 
processes. The Erks are activated by plethora of stimuli, including growth factors acting
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through receptor tyrosine kinases, cytokine binding to receptors that consequently 
activate tyrosine kinases or agonists of G protein-coupled receptors (reviewed in Kolch, 
2005). Erkl/2 has been shown to be involved in invadopodia-mediated ECM 
degradation, most likely by phosphorylating cortactin (Ayala et al., 2008) and by being 
activated by the small GTPase ARF6 (Tague et al., 2004) or paxillin (Badowski et al., 
2008).
The family of p21-activated kinases (PAK) comprises six isoforms - group A 
(PAK 1-3) and B (PAK 4-6) with partly overlapping but also clearly distinct roles. 
Generally, the substrates of conventional group A PAKs are involved in the regulation 
of adhesion and cytoskeletal events and are targets of small GTPases Racl and Cdc42 
(Lim et al., 1996). Interestingly, the PAK 1 gene maps to the l lq l3  amplicon, the very 
same region that encodes cortactin (Bekri et al., 1997). Consequently, PAK 1 over­
expression has been documented in a number of carcinomas (Kamai et al., 2010; Li et 
al., 2008; Lu et al., 2013). Specifically, PAK 1 phosphorylated cortactin on SI 13, 
causing its reduced binding to F-actin (Webb et al., 2006). The non-phosphorylatable 
SI 13A cortactin reduced invadopodia-dependent matrix degradation (Ayala et al., 
2008). Nevertheless, the role of PAK and possible involvement of its other substrates 
invadopodia is not widely studied and remains to be defined.
1.2.6.3 Phospholipases and regulation of invadopodia by phosphatidylinositols
The role of the class I phosphoinositide 3-kinases (PI3Ks) in invadopodia 
organisation has been repeatedly demonstrated by the use of PI3K inhibitors and
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siRNA-mediated silencing, which both led to reduced number and activity of 
invadopodia (Hoshino et al., 2012; Yamaguchi et al., 2011). Furthermore, expression of 
PI3K catalytic subunit pi 10a stimulated the degradation capability of breast cancer 
cells (Yamaguchi et al., 2011).
All class I PI3Ks phosphorylate phosphatidylinositol 4,5-bisphosphate 
[PtdIns(4,5)P2] at the D3 position to generate phosphatidylinositol 3,4,5-trisphosphate 
[PtdIns(3,4,5)Ps]. PtdIns(3,4,5)P3then either activates the classical, PDK-Akt dependent 
PI3K signalling pathway, or, alternatively, serves as a precursor lipid for PtdIns(3,4)P2. 
Altogether, all three types of phosphatidylinositols have been implicated in invadopodia 
formation (reviewed in Hoshino et al., 2013). PtdIns(4,5)P2 is primarily generated by 
type I phosphatidylinositol 4-phosphate 5-kinases (PIP5KI). Three isoforms of PIP5KI 
exist in the mammalian cells, whereof subcellular location is unique. At invadopodia, 
the a-isoform of PIP5KI (PIP5KIa) might locally produce PtdIns(4,5)P2 and cause its 
accumulation in the proximity of invadopodial protrusion (Yamaguchi et al., 2010). 
Consequently, both PIP5KIa and its product PtdIns(4,5)P2 are necessary for ECM 
degradation by breast cancer cells (Yamaguchi et al., 2010). As PtdIns(4,5)P2 regulates 
some actin-related proteins, such as N-WASP (Rohatgi et al., 1999; Rohatgi et al., 
2000) and cofilin (van Rheenen et al., 2007), it might directly control actin 
polymerization at invadopodia sites (reviewed in Hoshino et al., 2013).
PtdIns(4,5)P2-derived PtdIns(3,4,5)P3 could be dephosphorylated by specific 
phosphatase, possibly synaptojanin (Chuang et al., 2004), to form PtdIns(3,4)P2. Local 
accumulation of PtdIns(3,4)P2 is an early event in invadopodia formation that precedes
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the accumulation of Tks5 (Oikawa et al., 2008). Subsequently, Tks5 binding to 
PtdIns(3,4)P2 by its PX domain to commence invadopodia formation.
The remaining question is how phosphoinositide turnover is spatiotemporally 
regulated at invadopodia, as it seems that different phosphoinositides are involved in 
different stages of invadopodia formation.
1.2.6.4 Ras-superfamily of small GTPases
First identified as proto-oncogenes, the members of the Ras superfamily of small 
GTPases control a staggering variety of biological processes, including regulation of 
gene transcription, proliferation, motility, invasion, intracellular trafficking and actin 
cytoskeleton modification. Typically, these proteins function as molecular switches that 
cycle between an inactive GDP-bound and an active GTP-bound form. The exchange of 
GDP for GTP induces a conformational change that allows interaction with downstream 
effectors; this active state is terminated by hydrolysis of bound GTP to GDP. The 
activity of the hydrolytic cycle is primarily controlled by three sets of the accessory 
proteins: guanine nucleotide exchange factors (GEF), GTPase activating proteins (GAP) 
and guanine nucleotide dissociation inhibitors (GDI). The members of Ras superfamily 
fall into five subfamilies, named Ras, Rho, Rab, Ran and ARF, with distinct functions. 
In the following text, I will discuss only the small Ras GTPases, whose role at 
invadopodia has been demonstrated.
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The strongest evidence to date points to Cdc42 as a central small GTPase at 
invadopodia thanks to its induction of actin polymerization, probably owing to its 
ability to directly activate N-WASP and thereby promote Arp2/3 complex dependent 
actin polymerization (Rohatgi et al., 1999). When Cdc42 is down-regulated by RNA 
interference, or when a constitutively inactive mutant is transfected, invadopodia 
formation is inhibited in the metastatic MTLn3 (Yamaguchi et al., 2005), whereas 
dominant-active mutant of Cdc42 enhanced dot-like and diffused fibronectin 
degradation, respectively, in RPMI17951 melanoma cells (Nakahara et al., 2003) and 
GFP-tagged Cdc42 was localized at invadopodia in A375MM melanoma cells 
(Baldassarre et al., 2006). Similarly, Cdc42 ablation blocks invadopodia formation, 
while preventing the efficient targeting of MT1-MMP to the invadopodia (Sakurai- 
Yageta et al., 2008).
The involvement of other RhoGTPases has been also implicated in invadopodia 
biogenesis, with variable effects, though, probably because of their indirect role in the 
actin polymerization. Similarly to Cdc42, active RhoA triggered the association of 
exocyst complex subunit Sec8 with the polarity protein IQGAP (discussed in the section 
1.2.9) for the efficient targeting of MT1-MMP at sites of matrix degradation (Sakurai- 
Yageta et al., 2008) and accordingly the ablation of RhoA resulted in dramatic decrease 
of matrix degradation (Bravo-Cordero et al., 2011; Lizarraga et al., 2009; Roh-Johnson 
et al., 2013; Sakurai-Yageta et al., 2008), possibly also by affecting the actin-elongation 
factors formins (DRF1-3) (Lizarraga et al., 2009).
RhoC GTPase has been shown to affect invadopodia morphology and function 
without affecting their formation. After RhoC knock-down, melanoma cells rather that
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forming straight, long invadopodia, formed invadopodia that are wider and shorter. 
Against all the expectations, RhoC depleted cells degraded the matrix more efficiently, 
but failed in invasive migration. Therefore, it seems that invadopodial protrusions must 
be strictly focused for the efficient migration. Using Forster resonance energy transfer 
(FRET) RhoC biosensor, it was shown that active RhoC formed a ring around 
invadopodial core, thus confining the invadopodia-associated molecules to restrict the 
size and directionality of invadopodia. The intriguing hypothesis of zonal activation of 
RhoC is that it occurs through selective localization of the accessory proteins. In the 
same study, Bravo-Cordero et al. (2011) showed that inhibitory pl90GAP localized to 
the invadopodial core to block RhoC activity. Conversely, activatory pl90GEF was 
excluded from the core and was instead found in the ring of active RhoC. Further, the 
localized activity of RhoC led to zonal activation of cofilin. Unphosphorylated active 
cofilin was abundant within the invadopodial core, whereas inactive serine 
phosphorylated cofilin was present in the surrounding area to compartmentalize the 
actin-free barbed end formation (Bravo-Cordero et al., 2011). The importance of Rho 
activity at invadopodia is further supported by previous observations that 
phosphorylation of pl90RhoGAP was found to activate the membrane-protrusive 
activity required for invadopodia formation and cell invasion (Nakahara et al., 1998).
As mentioned above, accessory proteins modulate the activity of small GTPases 
through the regulation of the hydrolytic cycle of GTP. Among them, the known GEFs 
outnumber Rho family GTPases themselves (Schmidt and Hall, 2002); thus, it is likely 
that GEFs are the key in regulating the specificity of downstream signalling from Rho 
GTPases and their interaction with different effectors (Zhou et al., 1998).
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The functional consequence of GEF over-expression is to elevate cellular levels 
of activated Rho GTPases, hence deregulated GEF expression might lead to aberrant 
growth, invasiveness and/or increased metastatic potential. Although how GEFs are 
regulated is still unknown, they clearly represent powerful candidates as spatial and 
temporal Rho-GTPase regulators.
A first GEF be shown to have a role in invadopodia biology was Cdc42-specific 
GEF faciogenital dysplasia protein 1 (Fgdl), in a study showing that the Cdc42 GEF 
Fgdl is required for invadopodia biogenesis in melanoma, breast and prostate 
carcinoma cells. In addition, its expression levels correlated with the level of 
aggressiveness of the human prostate and breast cancer tumours. Fgdl appeared to be a 
transient component of invadopodia, in accordance with the stepwise formation and 
maturation of invadopodia. In detail, shortly after invadopodia initiation Fgdl locally 
accumulated at puncta with no underlying matrix degradation, which might be nascent 
invadopodia where Fgdl appears ahead of actin. Later on, structures where Fgdl co­
localized with F-actin and underlying degradation are described to be hilly active “early” 
invadopodia. On contrary, mature fully active invadopodia are Fgdl negative (Ayala et 
a l, 2009).
ADP-ribosylation factor 6 (ARF6) is a member of Ras superfamily of small 
GTPases and, like most GTPases, alternates between inactive GDP-bound active GTP- 
bound form. ARF6 has been intensely studied and especially in the context of clathrin 
independent endocytosis (CIE) and endosomal trafficking (Donaldson, 2003). The 
presence of glutamine and serine residues in the effector domain regions exclusively at
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ARF6 enables to control actin rearrangement, in the contrast to other members of Arf 
family (Al-Awar et al., 2000).
The endogenous ARF6 was localized at invadopodia in breast cancer cells 
(Hashimoto et al., 2004) and in melanoma cells (Tague et al., 2004) and the ARF6 
activity was required for invadopodia formation. The relevance of ARF6 in ECM 
degradation is supported by the direct correlation between ARF6 expression levels and 
the invasive phenotype (Hashimoto et al., 2004). The mechanism of action of ARF6 at 
invadopodia, however, is not completely defined but it is likely to be manifold. Firstly, 
the role of ARF6 in recycling of proteins from the cells surface might influence the 
availability of specific integrins that are employed in invadopodia initiation and 
function. Furthermore, ARF6-dependent endosomal trafficking may control delivery of 
a bulk membrane, where it is needed as a building block of various membrane 
protrusions, as it is documented at the leading edge of migrating cells (Tague et al., 
2004)
The ARF6 involvement in invadopodia formation comprises a complex array of 
downstream effectors. The ARF6-downstream effector AMAP1 and ARF6-GEF 
GEP100 are abnormally expressed in some breast cancers and the EGFR-GEP100- 
ARF6 not only stimulated matrix degradation but also disrupted E-cadherin-based cell­
cell adhesion (Morishige et al., 2008; Sabe et al., 2009). Similarly, the brain exclusive 
ARF6-GEF EFA6A promoted cell motility and invasion through ARF6/MEK/Erk axis 
(Li et al., 2006).
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1.2.7 Actin polymerization at invadopodia
The initiation of invadopodia by an appropriate signal is facilitated by 
reorganization of actin cytoskeleton. Two distinct types of F-actin network co- 
ordinately form invadopodia: the N-WASP-Arp2/3 complex-dependent branched actin 
filaments are formed at the base of invadopodia and the branched actin meshwork 
propels invadopodia into the underlying matrix, similarly to lamellipodia protrusions. 
Alternatively, the further extension of invadopodia requires parallel arrays of bundled 
actin filaments, which are suggested arranged perpendicularly to the substrate, along the 
length of invadopodia.
According to the currently accepted stepwise model of invadopodia formation 
and maturation, invadopodia formation starts by accumulation of actin and cortactin at 
sites of cell adherence to ECM, with cortactin potentially recruiting other components 
of invadopodia machinery (Artym et al., 2006; Oser et al., 2009), and consequently 
promoting the Arp2/3 complex-mediated actin polymerization. Similarly, N-WASP 
upstream activators are required for invadopodia formation, such as Cdc42, non- 
catalytic region of tyrosine kinase adaptor protein 1 (Nckl) and WASP interacting 
protein (WIP). Of note, on the contrary of podosomes, invadopodia formation and 
degradation activity was markedly suppressed by depletion of Nckl but not Grb2 
(Yamaguchi et al., 2005).
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The elongation of invadopodia is driven by constant growth of parallel actin 
filaments present along the length of invadopodia. The extension is suggested to be 
aided by actin nucleation factors represented by formins (Lizarraga et al., 2009), whilst 
the bundling and stabilization is coordinated by actin cross-linker fascin (Li et al., 2010). 
Additionally, member of Ena/VASP family, Mena and its invasive-specific splicing 
form Mena1^  (Lizarraga et al., 2009). Invadopodia extension is further supported by 
actin severing activity of cofilin, which generates free barbed ends indispensable for 
addition of free G-actin monomers and growth of actin filaments. Clearly, cofilin is not 
essential for invadopodia initiation, but it is important for the stabilization and 
maturation process. In particular, its depletion resulted in the formation of small, short­
lived and thus poorly degrading invadopodia.
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Fig. 1.4. The sequential model of invadopodia formation. The
basic shape of the structure (top), a representation of key proteins 
in relation to the cell membrane (middle) and a molecular 
overview (bottom). A) Initiation: upon growth factor stimulation 
(EGF, PDGF, TGFP), Src-phosphorylated TKS5 localize to 
PtdIns(3,4)P2-rich regions, which leads to recruitment of cortactin. 
Consequently, PI3K and PKC are activated. B) Formation: 
recruitment and activation of the actin polymerization machinery, 
including ARP2/3 and WIP, and the phosphorylation of key 
proteins , such as cortactin, TKS 5, fascin, AFAP110, together 
withthe production of reactive oxygen species (ROS). TKS5 binds 
NCK1, NCK2, GRB2 and N-WASP. Cortactin associates with N- 
WASP and the ARP2/3 complex and generates a complex of WIP 
and dynamin during invadopodia formation. Phosphorylation of 
both cortactin and TKS5 regulate invadopodium formation. C) 
Maturation: degradation of the ECM mediated by the secretion of 
MMP2 and presence of MT1MMP at the tip of invadopodia. At this 
stage, dephosphorylated cortactin blocks the severing ability of 
cofilin and enables the stabilization of invadopodia. Dotted arrows 
indicate a regulatory pathway for which the mechanism is 
unknown. Dashed lines represent an enzyme-substrate interaction. 
P, phosphate; RTK, receptor Tyr kinase. Image taken Murphy and 
Courtneidge (2011)
45
1.2.8 Protease-dependent degradation of ECM
The main function attributed to invadopodia is that of ECM degradation, 
facilitated by focalized delivery of the ECM-degrading proteases. Indeed, in the initial 
studies on invadopodia biology, MMP2 and the surface expressed serine protease 
seprase were found at invadopodia, directly correlating with the invasive potential of 
tumour cells (Monsky et al., 1993; Monsky et al., 1994). In fact, increased protease 
activity is known to enhance the numbers of invadopodia (Artym et al., 2006; Branch et 
al., 2012; Clark et al., 2007; Steffen et al., 2008), and the broad-spectrum protease 
inhibitor Batimastat (BB94) blocks invadopodia formation (Ayala et al., 2008). Thus, a 
feedback loop appears to exist between invadopodia formation and protease activity. 
Among the variety of extracellular proteases expressed by human cells, matrix 
metalloproteases emerged as important enzymes involved in the proteolytic activity of 
invadopodia. Members of the MMP family (25 of them identified in humans) are 
multifunctional zinc-dependent enzymes that collectively degrade almost all 
constituents of the ECM (reviewed in Egeblad and Werb, 2002). The majority of MMPs 
is secreted in the extracellular environment, except for seven integral membrane 
proteases. The insertion of membrane-bound proteases in the membrane is facilitated 
either by single type I transmembrane domain (MMP 14, 15, 16 and 24 or, alternatively, 
MT1-, MT2-, MT3- and MT5-MMP), a glycosphingolipid anchor (MMP 17 and 25 or 
MT4- and MT6- MMP) or a type II transmembrane domain (MMP23). All MMPs share 
a common structure that consists of a signal peptide, a propeptide and a catalytic 
domain. MMPs are thus expressed as zymogens (proenzymes) and require proteolytic
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cleavage of the propeptide to become active. In most cases, proteolytic activation occurs 
upon secretion in the extracellular milieu and is facilitated by other activated MMPs or 
serine proteases. MT-MMPs can also be activated by intracellular furin proteases before 
they reach the cell surface (Egeblad and Werb, 2002).
The paradigmatic MT1-MMP is generally considered a master regulator of 
protease-mediated cell invasion (Holmbeck et al., 2004; Sabeh et al., 2004; Seiki and 
Yana, 2003) and its key role at invadopodia-mediated degradation of the ECM has been 
proven repeatedly in diverse cell models (Artym et al., 2006; Branch et al., 2012; Clark 
et al., 2007). MT1-MMP is expressed as an enzymatically inactive 64 kDa zymogen 
(pro-MTl-MMP) and is further processed by furin-mediated proteolytic cleavage (Sato 
et al., 1996) upon its exit from Golgi prior to the arrival to the plasma membrane, 
originating in an enzymatically active 54 kDa fragment. Remarkably, a majority (80%) 
of pro-MTl-MMP is sorted to raft fractions and only a minor (20%) detergent-soluble 
fraction undergoes intracellular processing to the mature form (Mazzone et al., 2004). 
Although raft-associated pro-MTl-MMP does not directly function as a protease, it may 
still indirectly influence the degradation process, for example by binding of pro-MMP2 
to activate it (Cao et al., 1996). Active MT1-MMP can directly degrade a variety of 
ECM components, such as gelatin, fibronectin, vitronectin, collagens I-III, laminin 1 
and 5, fimbrin and proteoglycans. Integrins can also be cleaved by MT1-MMP, 
resulting in enhanced outside-in signalling.
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1.2.9 Membrane trafficking to invadopodia
The trafficking of MT1-MMP to invadopodia sites serves as an excellent case in 
point to illustrate the complexity of the regulation of these structures and the tight 
balance between exocytosis and endocytosis at the sites of focal degradation. MT1- 
MMP is delivered to invadopodia in multiple ways (reviewed in Fritolli et al., 2010). 
First, targeting of MT1-MMP depends on the secretory pathway that converges on the 
actin cytoskeleton and the exocytic machinery. The exocyst is an octameric protein 
complex, consisting of Sec3, Sec5, Sec6, Sec8, SeclO, Secl5, Exo70, and Exo84, that 
mediates the tethering of secretory vesicles to the plasma membrane for polarized 
exocytosis. Importantly, activated Cdc42 and RhoA promoted binding to polarity 
regulator Ras-like GTPase activating protein IQGAP, and this interaction depended 
specifically on the exocyst subunits Sec3 and Sec8 (Sakurai-Yageta et al., 2008). The 
next key step in regulated exocytosis is the fusion between the donor and the acceptor 
membrane, facilitated by SNAREs (soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor). At invadopodia, the vesicular SNARE TI-V AMP/VAMP - 
7 is required for MT1-MMP accumulation at the sites of degradation and for the 
efficient invadopodia formation in the breast cancer cells (Steffen et al., 2008). 
Accordingly, the endosomal SNAREs VAMP-3 and syntaxin 13 along with plasma 
membrane SNARE SNAP23 affect MT1-MMP trafficking and the invasive potential of 
fibrosarcoma cells (Kean et al., 2009). A fraction of MT1-MMP also originates from 
endocytic recycling. MT1-MMP is internalized, trafficked and recycled both through 
clathrin- dependent and caveolae-mediated endocytosis, and destined to endosomal and
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Fig. 1.5. MT1-MMP trafficking. This schematic drawing 
represents intersection between biosynthetic/secretory and endo- 
/exocytic pathways involved in the localized delivery of MT1- 
MMP. Adapted from Frittoli et al., 2010.
lysosomal compartments for either recycling or degradation. Additionally, MT1-MMP 
can be mobilized from intracellular storage by Rab8-dependent polarized exocytosis 
(Bravo-Cordero et al., 2007). Rab8 is a small GTPase of Rab subfamily that plays a 
pivotal role in the membrane traffic by determining the identity of the transported 
vesicles (Zerial and McBride, 2001). Another layer of complexity of proteases 
trafficking to the invadopodia sites has been added by a recent study on MMP2 and 
MMP9. In this case, small GTPase Rab40 was required for sorting of MMP2/9 in 
VAMP4 positive secretory vesicles and efficient degradation of matrix in breast cancer 
cells (Jacob et al., 2013). The authors also proposed that MMP2/9 invadopodia targeting 
is independent of endocytic transport.
1.2.10 Role of metabolism in the invadopodia formation
In the dense, disorganized primary tumours, cancer cells grow in low oxygen 
conditions. In such milieu, oxidative phosphorylation is impaired, potentially leading to 
adenosine triphosphate (ATP) deficiency. Cancer cells can adapt to such hypoxic 
conditions by switching to anaerobic metabolism, i.e., to glycolysis. Glycolytic 
metabolism, in turn, has lower energy yield compared to the Krebs cycle and cancer 
cells, indeed, exhibit a higher expression of glucose transporter GLUT (reviewed in 
Macheda et al., 2005) to meet increased nutrient demands. However, this metabolic 
adaptation presents a lethal risk to the cells due to the glycolysis-dependent increased 
production of H+. The adaptive response of tumour cells to high proton concentration is
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the over-expression and increased activity of pH-regulated transporters and enzymes 
(reviewed in Brisson et al., 2012).
A growing body of evidence suggests that hypoxic conditions might affect 
invadopodia biogenesis, although the key players have not been defined. The first study 
to analyze the functional and molecular relationship between hypoxia and invadopodia 
suggested that invadopodia formation is strongly affected by changes in cellular pH 
homeostasis, caused by Na+/H+ exchanger type 1 (NHE1) (Busco et al., 2010). NHE1 is 
involved in invadopodia formation in two ways. Firstly, NHE1 binded phosphorylated 
cortactin at the sites of invadopodia and the local cytosolic alkanization caused release 
of cofilin from cortactin to promote cofilin’s severing activity (Magalhaes et al., 2011). 
Secondly, NHE1 activity caused acidification of the peri-cellular space around 
invadopodia, which is necessary for proteolysis of ECM components (Busco et al., 
2010).
Diaz et al. (2013) proposed a signalling pathway that regulates invadopodia 
formation by coupling hypoxia inducible factor (HIF) la-activated cell-contact 
dependent signalling with paracrine activation of EGFR. In hypoxia, HIF-1-dependent 
induction of invadopodia formation is mediated by Notch. The subsequent Notch- 
dependent increase in ADAM 12 led to augmented shedding of HB-EGF, a potential 
ligand for EGFR (Diaz et al., 2013). Another study suggests a critical role for both Hif- 
la  and Hif-2a in hypoxia-induced cell motility and active invadopodia formation in 
melanoma cells lines derived from murine tumours (Hanna et al., 2013). In this case, 
Hif-la and Hif-2a coordinately activated parallel yet distinct pathways to induce SFK 
activation and ECM degradation. Specifically, Hif-la acted through platelet derived
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growth factor receptor (PDGFR)-MT1-MMP axis, whereas Hif-2a induced SFK 
activity and ECM degradation via FAK and release of MMP-2, respectively.
1.2.11 Invadopodia in a three-dimensional world
A highly controversial aspect of invadopodia biology is whether invadopodia 
really exist in vivo and whether they contribute to the tumour cell invasion and 
metastasis. Most of our knowledge of invadopodia comes from studies performed using 
flat two-dimensional (2D) substrates, where they form below the cell body, extending a 
few micrometers into the ECM scaffold producing punctuate-like small lytic foci. 
Whether these contacts, which have been exclusively defined in some cell culture 
systems, are experimental artefacts or have related counterparts in three-dimensional 
(3D) settings either in reconstituted ECM models or in vivo (i.e. within tissues) is 
incompletely defined. This does not undermine the fundamental importance of the 
information gleaned by studying invadopodia biology, but has important implications in 
establishing the immediacy of the translational potential of such studies.
As highlighted above, invadopodia-associated proteins, such as cortactin, WASP, 
Arp2/3, are misregulated in some cancer types and connected to metastasis formation, 
suggesting a correlation between actin dynamics leading to ECM degradation in vitro 
and the invasive potential of cancer cells in vivo (Vignjevic and Montagnac, 2008). A 
current approach to gain insight into invadopodia biology in physiologically more 
relevant condition is the use of matrices that attempt to mimic the native environment of 
tumours. There are two basic patterns of ECM organization in vivo in mammals. Thin
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and flat basement membrane, that consists primarily of type IV collagen and laminins. 
Underlying the basement membrane, the interstitial tissue is a thick 3D meshwork 
dominated by fibrillar collagen type I, which organizes into polymeric cross-linked 
network (Rowe and Weiss, 2009).
A initial study conducted by Friedl and Wolf (2008) using fibrillar collagen 
matrices or dermis slices suggested that invadopodia correspond to the lateral spikes of 
the migrating cells rather than to forward facing protrusions (Friedl and Wolf, 2008). 
However, this remains a speculation as no typically invadopodia-associated markers 
were used in this study. A modified version of the Boyden chamber invasion assay has 
also been used for the detailed study of invadopodia formation and structure. In this 
case, invasive colon cancer cells were plated on top of transwell filters coated with 
native basement membrane, and the composition and function were followed over time. 
Three stages were described over a period of seven days: first, formation of invadopodia 
and degradation of basement membrane; second, elongation of invadopodia beyond the 
membrane and inside the pores; and third, the maturation of invadopodia (Schoumacher 
et al., 2010). More recently, Magalhaes et al. (2011) used 3D matrices to show 
invadopodia as protrusive structures at the leading edge of migrating cells that 
contained invadopodial markers such as actin, cortactin and Tks5. Functionally, they 
were able to degrade the matrix in the direction of the movement (Magalhaes et al., 
2011). The identification of lytic protrusions in 3D tissue invasion, comparable to 
invadopodia, and the establishment of their relevance to invasive migration and ECM 
remodelling, however, remains to be determined. Ultimately, one would want to know 
when, where, and how invadopodia contribute to 3D cell invasion and tissue
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remodelling. A significant burden to 3D analysis in vivo and ex vivo is the technical one. 
Standard imaging approaches used in 2D settings face the problem of sample depth, 
focal plane, autofluorescence and signal-to-noise in 3D. Multiphoton (two-photon or 
non-linear) microscopy offers a good solution to aforementioned constraints of 3D 
imaging. Multiphoton excitation can reach substantially greater imaging depth while 
having reduced photobleaching and tissue damage. A by-product of multiphoton 
imaging is the occurrence of second and third harmonic generation (SHG and THG, 
respectively), that enable imaging of nonlinear scattering effects, thus allowing 
observation of the collagen and the tissue interface without endogenous labelling.
A major challenge of the invadopodia research field is to show that invadopodia 
markers indeed localize to the degradation-competent actin rich protrusions of the 
migrating tumour cells in vivo. As mentioned in the section of N-WASP, Gligorijevic et 
al. (2012) used a xenograft model containing the fluorescently labelled N-WASP 
ablated cells. In this study, 3D time-lapse imaging has been employed to follow the 
protrusion formation in the MTLn3 cell-derived xenograft tumours. Strikingly, these 
protrusions were positive for cortactin and associated with proteolytic activity, as 
revealed by cleaved collagen % staining (Gligorijevic et al., 2012).
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1.3 Cholesterol in biological membranes
Cholesterol is an essential molecular component of the eukaryotic cells, in 
which it is indispensable for growth and viability. Eukaryotic cells invest considerable 
energy to synthesize and tightly control this molecule that might be even toxic under 
certain circumstances. Utmost role of cholesterol is as a structural component of 
biological membranes that regulates diverse membrane characteristics, such as fluidity, 
permeability, thickness and phase order. Beside that, cholesterol serves as a precursor of 
bioactive molecules including steroid hormones, vitamin D, bile acid and oxysterols.
1.3.1 Biological membranes: Cholesterol and membrane viscosity
Biological membranes are circa 5 nm-thick lipid bilayers that form continuous 
barriers around the cell and the cellular compartments. Beside their role in cellular 
compartmentalization, biological membranes are fundamental platforms for signal and 
energy transduction, cell adhesion, cell motility and vesicular transport. Membrane lipid 
composition is not uniformly distributed and differs both vertically and horizontally; i.e. 
acros^ the different membrane organelles, between the two bilayer leaflets of any 
organelle (membrane asymmetry), and within the same monolayer, where microareas 
enriched in specific lipids are known to exist. These regions are typically referred to as 
cholesterol and sphingolipid domains, or generally lipid rafts, and they are dynamic
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proteo-lipid modules with specialised functions (Simons and Ikonen, 1997). Despite this 
complexity, lipid homeostasis is tightly maintained, as lipids are coordinately 
synthesised, catabolised, and shuttled from their sites of synthesis to their eventual 
intracellular destinations. The lipids of biological systems are either hydrophobic, 
containing non-polar groups only (e.g., triglycerides), or amphipathic, which means 
they feature both polar and non-polar groups.
The major structural amphiphathic lipids in biological membranes are 
glycerophospholipids, sphingolipids and cholesterol. The hydrophobic moiety of the 
glycerosphingolipids is diacylglycerol, which is covalently linked to two fatty acids of 
varying lengths. Glycerosphingolipids are subdivided in five major types depending on 
the polar head group: phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylinositol (PI) and phosphatidic acid (PA).
The hydrophobic backbone of the sphingolipids is ceramide. The polar head 
group could be either phosphocholine in case of sphingomyelin, the most prominent 
sphingolipid in mammalian membranes, or mono-, di- or oligosaccharides in which case 
glycolipids are formed.
Sterols have the most atypical architecture, as they consist of a short alkyl chain 
and a nearly planar assembly of four rings. The only polar element of the sterols is a 
single hydroxyl group. In detail, cholesterol contains a single hydroxyl group at carbon 
3, a double bond between carbons 5 and 6, two methyl groups at carbon 18 and 19, and 
an iso-octyl hydrocarbon side chain at carbon 17 (Ohvo-Rekila et al., 2002). The 3D 
structure results in a rigid planar four-ring nucleus with the 3-OH group, the two
56
A l c o h o l
G lycerol
phophatidylethanolamine
B
A l c o h o l
sphingomyelin
" X  'O X C .  CH-. ^
W ® N5CH5.H
H OH
galactosylceramide
A lip h atic  ch a in  
S teran e
cholesterol
Fig. 1.6. Membrane lipids, (a) The glycerophospholipid backbone 
is made up of diacylglycerol, with two acyl chains, one of which 
(sn-2) bearing one or more cis double bonds. The head group can 
be serine, inositol, ethanolamine, choline or glycerol, (b) 
Sphingolipids consist of sphingosine backbone which is attached to 
a fatty acid and polar headgroup. In sphingomyelins, the head 
group is phosphocholine choline, while in glycosphingolipids 
(GSL) is made up of one or more sugars, (c) The polar head group 
of cholesterol is a single OH group, whereas the hydrophobic 
moiety contains an iso-octyl carbon chain linked to a sterane- 
derived unit. Image adapted from Fantini (2002).
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methyl groups and the side chain on the same side in the p-configuration (Bittman, 
1997).
Cholesterol is a major determinant of the biophysical properties of cell 
membranes. Membrane viscosity, as opposed to membrane fluidity, is a parameter used 
to describe an ease of movement of a particle within the membrane. Cholesterol 
modulates membrane viscosity by increasing it at higher temperatures and decreasing it 
at lower ones, thus acting as a membrane fluidity buffer (Nipper et al., 2008). 
Nevertheless, there are some indications that augmenting cholesterol might even reduce 
the viscosity of the plasma membrane of the aortic endothelial cells (Byfield et al., 
2005). Moreover, specialized membrane domains such as the lipid rafts, influence and 
to certain extent spatially regulate the rigidity of the membrane. For example, inhibition 
of ABCA1 transporter, which is known to distribute raft cholesterol to non-raft regions, 
significantly alters the viscosity gradient in migrating keratinocytes, resulting in the 
inhibition of migration (Klein et al., 2012; Zarubica et al., 2009). Up to now, only few 
studies have shown a direct correlation between local microviscosity and cholesterol 
content in living cells, while comprehensive analysis is often burdened by imaging 
tools. There are a number of methods that have been developed to monitor the changes 
in the viscosity, amongst them fluorescence recovery after photobleaching (FRAP), 
environment sensitive dyes and nuclear magnetic resonance, which differ in sensitivity 
and robustness. Of note is the lipophilic fluorescent probe Laurdan with the distinct 
ability to sense the changes in the polarity of its environment. In the lipid bilayers, 
Laurdan undergoes a spectral shift in the presence of water, informing about water
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penetration, a property related to lipid packing and membrane viscosity (Kaiser et al., 
2009).
Changes in membrane viscosity represent a key tool in regulation of the 
membrane properties in physiological conditions and in the pathogenesis of diseases, 
such as atherosclerosis, hypercholesterolemia, Alzheimer disease and cancer. For 
example, in the cancer cell, augmentation of membrane fluidity is instrumental for cell 
migration and might facilitate the migratory potential of cancer cells by enhancing their 
deformability. Although sphingolipid/cholesterol association mediates the increased 
order of lipid rafts (Simons and Sampaio 2011), cholesterol fluidizes sphingolipid 
model membranes (Simons and Vaz 2004). Cancer cell membranes contain more 
cholesterol-rich lipid rafts (Li et al., 2006) and exhibit increased fluidity (Zeisig et al., 
2007) relative to normal cells. It has been also shown that increased membrane fluidity 
correlates with changes in malignancy in experimental models.
1.3.2 Biosynthesis of cholesterol
Biosynthesis of cholesterol is a long and complex process consisting of more 
than 30 reactions, which were mostly unravelled by Konrad Bloch and Fyodor Lynen, 
who were awarded the Nobel Prize for their work in this topic in 1964. The greater part 
of cholesterol biosynthesis occur in the endoplasmic reticulum (ER). The initial reaction 
is the condensation of acetyl-coenzyme A and its derivate acetoacetyl-coenzyme A. The
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product of this reaction, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) is further 
reduced to mevalonate by the enzyme HMG-CoA reductase (HMGR). This step is of a 
particular importance as it is irreversible and rate limiting for the biosynthetic pathway. 
Indeed, the blood cholesterol-lowering drugs statins inhibit cholesterol synthesis at this 
step. Subsequently, mevalonate is converted into isopentyl pyrophosphate in three ATP- 
dependent reactions. Isopentyl pyrophosphate is a key precursor of all isoprenoids, 
which form the structural basis of many vitamins, pigments and precursors of sex 
hormones. In the next step of the biosynthesis, the 5-carbon isopentylpyrophosphate 
condenses with itself in multiple steps to form the 30-carbon squalene.
Finally, the linear squalene is cyclized to form lanosterol leading to the typical 
sterol tetracyclic fused ring skeleton in an aerobic reaction. Altogether, there is 19 
different enzymatic reactions and 12 intermediates between the first steroid intermediate 
lanosterol and the final product cholesterol (Gaylor, 2002). Functionally, this complex 
process could be described as a progressive streamlining of the hydrophobic surface of 
sterol by removal of the 1-3 CH3 groups that protrude from the flat surface of the 
steroid ring (Mouritsen and Zuckermann, 2004). The post-lanosterol steps of cholesterol 
biosynthesis had been divided into Bloch and Kandutsch-Russell pathways that share 
the same enzymes but differ at the stage when C24 double bond is reduced. 
Consequently, cholesterol biosynthesis can continue with either 7-dehydrocholesterol 
(Kandutsch-Russell pathway) or desmosterol (Bloch pathway) as the penultimate 
precursor of cholesterol. The functional importance of having two distinct pathways is 
not well understood. Interestingly, there is evidence of an age-related differential use of 
the pathways. For instance, in young mice, brain cholesterol is synthesised mainly via
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the desmosterol pathway, while in older mice via the 7-dehydrocholesterol pathway 
(Lutjohann, 2002).
1.3.3 Subcellular distribution of cholesterol
Cholesterol is not evenly distributed within the cell. The main cholesterol 
biosynthetic compartment, the ER, along with mitochondria and cis-Golgi, contains 
very little cholesterol. ER cholesterol concentration is estimated to be as low as 1% of 
total cholesterol, whereas the highest concentration of cholesterol is at the plasma 
membrane, where it constitutes about 40% of total lipids and represents 65-80% of total 
cellular cholesterol (Maxfield and Wustner, 2002). Furthermore, a substantial amount of 
cholesterol has been detected in the membrane domains of endocytic pathway,
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specifically in the internal vesicles of multivesicular bodies (Mobius et al., 2003; 
Simons and Ikonen, 1997) and the endocytic recycling compartment (ERC) (Hao et al., 
2002; Ohvo-Rekila et al., 2002). Intracellular compartments in vesicular contact with 
the plasma membrane, such as lysosomes and trans-Golgi, have intermediate cholesterol 
content. How the gradient across the different membranes of the secretory pathway is 
maintained, remains elusive. Two main theories have been proposed. Firstly, cholesterol 
might be sorted into vesicles heading towards the plasma membrane but excluded from 
retrograde transport. Secondly, the differential distribution of cholesterol in particular 
membranes could depend on membrane lipid composition. According to the condensed 
complex model, cholesterol affinity for the different lipids varies, thus cholesterol 
builds more stable complexes with some lipids compared to others.
As mentioned previously, cholesterol is synthesized in the low cholesterol ER, 
thus a mechanism must be in place that helps to keep the cholesterol levels low. An 
important buffering mechanism to control the levels of unesterified cholesterol in this 
compartment is esterification by acetyl-coenzyme A acetyltransferase (ACAT). 
Esterified cholesterol is then transported to the lipid droplets or packed into lipoprotein 
particles.
1.3.4 Intracellular cholesterol transport
De novo synthesised cholesterol leaves the ER rapidly, in an energy dependent 
manner and with a halftime of 10-20 min (Bittman, 1997; DeGrella and Simoni, 1982). 
Brefeldin A, a well known inhibitor of anterograde transport that disrupts the Golgi
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complex, has little effect on the kinetics of cholesterol arrival to the PM (Urbani and 
Simoni, 1990), suggesting that cholesterol is transported in a non-vesicular fashion. The 
non-vesicular transport of sterols and other lipids may be facilitated by a family of 
cytosolic lipid transfer proteins (LTPs), inter-organelle membrane contacts or 
combinations thereof. Further support for the non-vesicular sterol transport hypothesis 
comes from yeast with conditional defects in proteins involved in intracellular vesicular 
transport in which transport of the cholesterol yeast homologue ergosterol remained 
unaltered (Schnabl et al., 2005). There are many candidates for sterol transport 
including the oxysterol-binding protein related proteins (ORPs) (Im et al., 2005; 
Lutjohann, 2002) and caveolins (Smart et al., 1996; Uittenbogaard and Smart, 2000).
1.3.5 Cholesterol efflux
Because mammalian cells are unable to degrade cholesterol, they need to 
remove cholesterol via regulated secretion. The secretion of cholesterol by non-hepatic 
cells, also referred to as reverse cholesterol transport, is an important cellular 
homeostatic mechanism controlling the levels of free cholesterol by export to high- 
density lipoprotein (HDL) particles. Trans-membrane proteins from the family of ATP- 
binding cassette (ABC) transporters have emerged as main facilitators of this process, 
with the ubiquitously expressed ABCA1, the protein defective in Tangier disease (Rust 
et al., 1999). Binding of the circulating extracellular acceptor of cholesterol, the lipid- 
poor form of apoliprotein A-I (apoA-I) to the membrane-bound ABCA1 transporters 
triggers a multi-step process, which facilitates the transfer of phospholipids and
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cholesterol to the HDL. HDL then enter the circulation and are cleared from the blood 
by liver and steroidogenic cells in a scavenger receptor B1 (SRBl)-dependent fashion 
(Valacchi et al., 2011). In the liver, the obligate heterodimers ABCG5/ABCG8 are 
involved in the secretion of cholesterol into bile (Graf et al., 2003).
It is worth noting that cholesterol elimination from macrophages is a crucial 
process in atherosclerosis. Another ABC transporter, macrophage-specific ABCG1, 
cooperates with ABCA1 to facilitate further loading of lipids to nascent HDL (Gelissen 
et al., 2006). Combined knock-out of ABCA1 and ABCG1 in mice has indicated that 
the synergetic action of both transporters in mediating cholesterol efflux form 
macrophages is of crucial importance in prevention of atherosclerosis in vivo (Yvan- 
Charvet et al., 2007).
1.3.6 Cholesterol uptake
In addition to cholesterol biosynthesis, cells can acquire cholesterol from the 
extracellular environment via receptor-mediated uptake of lipoprotein particles. Low- 
density lipoprotein receptor (LDL-R), present at the cell surface, binds low-density 
lipoprotein (LDL) containing esterified cholesterol and lipids. The complex is then 
endocytosed by clathrin-coated vesicles that pinch off from the plasma membrane. As 
the complex travels along the endocytic pathway, the pH of the vesicles decreases, 
resulting in conformational change of LDL-R and subsequent release of its cargo. At 
this point, LDL-R is either recycled back to the plasma membrane or targeted for 
degradation in lysosomes. LDL-cholesterol esters are hydrolysed in late endosomes by
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acid lipase to form unesterified free cholesterol ready for cellular needs. Exit of 
cholesterol from the multivesicular late endosomes is mediated by late endosomal 
Niemann-Pick type C proteins (NPC) 1 and 2. Although the precise mechanism is not 
clear, loss of function of either protein leads to Niemann-Pick disease characterised by 
the retention of LDL-derived unesterified cholesterol in the late endosomal 
compartment. A soluble NPC2 binds cholesterol and delivers it to membrane-bound 
NPC 1 that incorporates the sterol in the late-endosomal/lysosomal membrane (Kwon et 
al., 2009).
1.3.7 Transcriptional control of cholesterol homeostasis
Cholesterol homeostasis is also regulated by two main nuclear transcriptional 
receptor systems, the sterol regulatory element binding proteins (SREBP) and the liver 
X receptors (LXR). SREBP is a transmembrane protein harboured in the ER by binding 
to SREBP cleavage activating protein (SCAP). In cholesterol-poor conditions, the 
conformational change abrogates SCAP binding with insulin-induced gene 1 (Insig 1). 
As a result SREBP is transported to Golgi complex, where it undergoes proteolytic 
cleavage. Upon transport to the nucleus, the processed fragment acts as a transcription 
factor that activates the expression of genes containing a sterol regulatory element, such 
as HMCoA and LDL, thus activating the cholesterol biosynthesis and uptake, 
respectively. On the contrary, activation of the LXR transcriptional system leads to 
reverse cholesterol transport. LXRs sense the cholesterol levels by binding the oxidized 
form of cholesterol, oxysterols. Upon activation, LXRs alter the transcription of
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proteins involved in reverse cholesterol transport (reviewed in Tontonoz and 
Mangelsdorf, 2003).
1.3.8 Oxysterols
Oxysterols are the oxygenated derivates of cholesterol, which are produced by 
either oxidation of cholesterol itself or by an enzymatic reaction (reviewed in Brown 
and Jessup, 2009). Typically, they are present at 1000-fold lower concentrations 
compared to cholesterol. The hydroxylated sterols are more hydrophilic and can cross 
the biological membranes more readily than cholesterol. As first proposed by 
Kandutsch, certain oxysterols may serve as a sensor and modulators of cholesterol 
homeostasis (Kandutsch et al., 1978). The oxysterols involved in this cholesterol 
biosynthesis feedback regulation can be divided in four categories according to their 
mechanism of action: 1) suppressors of HMg-CoA reductase; 2) LXR ligands; 3) 
suppressors of SREB; 4) activators of cholesterol.
Of interest, 24(S), 25-epoxycholesterol is unique among oxysterols in that it is 
not derived from cholesterol. Instead, it is produced directly via a shunt in the 
mevalonate pathway. 24(S), 25—epoxycholesterol affects cholesterol homeostasis by all 
three main modes of cholesterol regulation: inhibition of cholesterol synthesis via 
stimulation of HMG-CoA reductase degradation and suppression of SREBP activation; 
inhibition of re-uptake via suppression SREBP activation and stimulation of efflux via 
LXR (Brown, 2009).
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1.3.9 Cholesterol-lowering drugs and their possible implication in cancer therapy
The most prescribed cholesterol-lowering drugs, the statins (also among the 
most prescribed drugs in any class), are inhibitors of HMG-CoA reductase and as such 
studied both intensively and extensively. First isolated from fungi strain as mevastatin 
(also called compactin), the first chemically derived compound, lovastatin, was 
marketed in the late 80’s with other statins soon to follow (reviewed in Gelissen and 
Brown, 2011). Interestingly, population studies suggested that, in addition to the 
beneficial effects in prevention of cardiovascular diseases, administration of statins 
correlates with reduced incidence of a number of pathologies, such as melanoma, breast, 
prostate and colon cancer (Hindler et al., 2006) and continuous administration of 
standard doses of statins is beneficial and might be especially helpful in preventing 
certain types of tumours, as first reviewed by Solomon and Freeman (Solomon and 
Freeman, 2008). A most studied point in case is prostate cancer (PCa) (recent reviews 
Krycer et al., 2013; Moon et al., 2013; Pelton et al., 2012). Early evidence of an 
association between cholesterol and PCa arose from studies on Japanese citizens, who 
had a manifold increased risk of PCa upon immigration to the United States, implicating 
high cholesterol as a culprit. Since then, the link between high cholesterol levels and 
prostate cancer risk has been studied in numerous epidemiological studies, including 
large population studies of cholesterol and disease, observational studies of cholesterol 
and PCa, observational studies of cholesterol-lowering drugs and PCa, and randomized 
trials of statins that report on cancer (reviewed in Pelton et al., 2012). Although the 
recent literature indicates that long-term statin therapy is chemopreventive against
68
aggressive PCa, large randomized trials of statin drugs that report on cancer (including 
PCa) do not support this claim. Solomon and his colleagues previously expressed 
several concerns about such all-cancer studies: their relatively short duration, relatively 
few PCa cases, inconsistency in recording of PCa grade or stage, large crossover of 
patients from control to statin groups, and the over-representation of least potent statin, 
pravastatin. In aggregate, whether or not statin-mediated lowering of cholesterol has a 
positive impact on cancer risk has been a subject of a numerous studies, although with 
conflicting results due to the diverse methodologies used in the studies, inconsistency in 
the duration, the prostate cancer markers and definition of terms such as low cholesterol. 
Nevertheless, the recent observational studies on the statins role in prostate cancer are 
supportive of the hypothesis that statin use reduces risk of advanced prostate cancer. In 
two independent studies Platz and colleagues showed in an analysis aimed specifically 
at prostate cancer incidence that there is no association between overall prostate cancer 
risk and statin use. In contrast, longer statin use was associated with advanced disease 
risk and development of a more dangerous, castration-resistant stage of PCa. Several 
more studies from independent groups largely confirmed this observation of that statins 
reduce the risk of aggressive PCa (Flick et al., 2007; Geybels et al., 2013; Jacobs et al., 
2007). For example, a recent study revealed in 10 years follow-up a drastic reduction of 
prostate cancer-specific mortality in statin users. However, the study demonstrated that 
statins do not have an effect on progress or recurrence (Geybels et al., 2013). In 
conclusion, it appears that statins might not prevent risk of early stage prostate cancer, 
but affect progression to more agressive phenotypes and to reduce mortality.
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The protective effect of statins is further supported by number of pre-clinical 
studies. By exploring the effect of statins on tumourigenesis at the molecular level, it 
has been confirmed that statins may help to keep under control a range of cellular 
functions involved in tumour initiation, growth and invasion. Whilst inhibiting the early 
step in the cholesterol biosynthetic pathway, statins inhibit synthesis of non-cholesterol 
synthetic intermediates, too. Most probably the beneficial effects of statins derive in 
vivo from lowering serum cholesterol, whereas extrahepatetic levels of statins are 
generally very low, and thus it is unlikely that statins accumulate in the other tissues at 
sufficient concentration to promote any sustained local effect (Solomon and Freeman, 
2008; Solomon and Freeman, 2011). Alternatively, tumour growth might be affected by 
the availabity of circulating cholesterol. Epidemiological studies regarding statins thus 
report on the effect of lowering of circulating cholesterol, or LDL, respectively.
Currently, several clinical trials on statins (simvastatin and atorvastatin- see 
www.clinical-trials.gov. identifiers NCT00572468, NCT01821404, NCT01759836, 
NCTO1220973, NCT01561482) are ongoing to assess the effect on various parameters, 
such as histological and circulating biomarkers (Moon et al., 2014).
In summary, critical evaluation of the epidemiological data supports the 
beneficial effect of statins, and enhanced cholesterol lowering, in prostate therapy, and 
several studies are underway. One such approach would be to employ statins, or other 
cholesterol lowering drugs, as an adjuvant therapy to standard cancer treatment.
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1.4 C-terminal Src kinase: The regulation of Src family kinases
The Src family kinases (SFK) are vitally important for the control of an array of 
signalling networks involved in cell proliferation, cytoskeleton organization, 
metabolism, motility, differentiation and in just about any cellular activity. The SFKs 
represent the largest family of non-receptor kinases in mammalian cells and comprise 
nine members, Src, Yes, Fyn, Fgr, Lyn, Hck, Lck, Blk, Yrk, of which Src, Fyn and Yes 
are ubiquitously expressed. SFKs share five similar functional domain arrangements, 
with an N-terminal domain followed by three domains designated as Src-homology 
(SH) region, SH3, SH2 and SHI (catalytic) domain and a C-terminal tail with a 
regulatory tyrosine.
1.4.1 Regulation of SFK activity
The structural similarities account for common mechanisms of regulation of the 
SFK activity: 1) fatty acylation of N-terminal domain regulates their membrane 
association and subcellular distribution; 2) once phosphorylated, the tail inhibitory 
tyrosine binds intramolecularly to the SH2 domain, thus maintaining the kinase in a 
closed, inactive conformation (reviewed in Ingley, 2008).
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The poorly conserved N-terminal region, sometimes called unique domain, is 
the most divergent part of SFKs and is believed to provide functional specificity to each 
family member, as the status of fatty acylation has been shown to regulate their 
subcellular location (reviewed in Resh, 1999). All family members are co- 
translationally myristoylated on the terminal glycine. Myristoylation mediates 
attachment to the inner surface of bilayered membrane. In addition, the unique domain 
could bear another lipid modification, reversible post-translational palmitoylation at 
multiple cysteine residues.
Tyrosine phosphorylation is the most significant mode of SFK regulation. All 
SFKs possess two tyrosine motifs that regulate activity in opposing ways. 
Phosphorylation of the tyrosine within the activation loop confers full activity of the 
kinase, while the C-terminal residue is phosphorylated in the inactive enzyme. The 
latter can interact with the SH2 domain intramolecularly, which makes the SH2 domain 
a key regulator of allosteric kinase regulation. In summary, the complex regulatory 
mechanism allows multiple levels of kinase activity, starting from 1) fully active form, 
where the activatory tyrosine within the A-loop is phosphorylated; 2) partially active 
form, where the activatory tyrosine is not yet phosphorylated; 3) closed inactive 
conformation.
1.4.2 Csk protein structure and catalytic function
The main physiological inhibitor of SFKs is the C-terminal Src kinase (Csk), 
another non-receptor tyrosine kinase with a molecular mass of 50 kDa, discovered in
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the late 80’s (Okada and Nakagawa, 1988). The structural organization of Csk and its 
homologue Csk-homologue kinase (Chk) is very similar to that of SFKs. However, they 
are some key differences. The distinctive feature of Csk is the absence of an 
autophosphorylation site, inhibitory tyrosine and N-terminal fatty-acyl modification. As 
a consequence, Csk activity is regulated in a distinct fashion, which will be discussed in 
the next section.
Each domain of Csk plays a role in the interaction with various binding partners. 
The catalytic domain (SHI) of Csk binds and phosphorylates all nine members of the 
SFK family (reviewed in Ingley, 2008); the phospho-tyrosine binding SH2 domain 
binds various scaffolding proteins, such as the ubiquitiously expressed Csk-binding 
protein/Protein associated with (Cbp/PAG) (Brdicka et al., 2000; Kawabuchi et al., 
2000), caveolin-1 (Cao et al., 2002), insulin receptor substrate-1 (IRS-1) (Tobe et al., 
1996), paxillin (Schaller and Parsons, 1995) and LIME (Brdickova et al., 2003). The 
inhibitory action of Csk might be coupled with the dephosphorylation of the activatory 
SFK tyrosine by a phosphatase that associates with Csk.
1.4.3 Regulation of Csk activity
Csk lacks both a trans-membrane domain and fatty-acyl modification, and it is 
thus predominantly localized in the cytosol. Therefore, Csk seems to be primarily 
regulated spatially than catalytically (Howell and Cooper, 1994). The investigation of 
the mechanism underlying the plasma membrane localization of Csk has led to the 
identification of functionally related scaffolding proteins that bind Csk in a
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phosphorylation dependent manner and thus bring it to the plasma membrane in close 
proximity to its membrane-associated substrates (Brdicka et al., 2000; Brdickova et al., 
2003; Cao et al; 2002; Kawabuchi et al., 2000). This creates a negative feedback loop 
by associating active SFKs with their suppressor Csk. Furthermore, binding to the 
adaptors can fully activate the enzymatic activity of Csk by inducing a conformational 
change in the catalytic domain, as shown in case of binding of Csk to phosphorylated 
Cbp/PAG (Takeuchi, 2000).
In addition to its spatial regulation, other mechanisms are involved in the 
regulation of the phosphotransferase activity of Csk. Firstly, Gpy upregulates Csk 
activity, probably by binding to the catalytic domain and by covalent modification 
(Lowry et al., 2002). Secondly, Csk is in vitro and in vivo phosphorylated on Ser 364 by 
protein kinase A (PKA) (Vang et al., 2001), leading to increased Csk activity due to 
altered interaction between the catalytic and SH3 domains (Yaqub et al., 2003).
1.4.4 Adaptor proteins -  Cbp/PAG
The mechanism underlying cell membrane localization of Csk has been 
investigated and has led to the identification of adaptor proteins (Ingley, 2009) 
including the phosphoproteins Cbp/PAG (Kawabuchi et al., 2000), LIME (Brdickova et 
al., 2003) and caveolin 1 (Cao et al., 2002). In this section, I will discuss Cbp/PAG.
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Fig. 1.8. Model of Csk activation by Cbp/PAG. Image taken 
from Okada (2012).
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The Csk-binding protein/phosphoprotein associated with glycosphingolipid- 
enriched domains (Cbp/PAG) (Brdicka et al., 2000; Kawabuchi et al., 2000) is 
characterized by a short extracellular domain (16-18 amino acids), a single trans­
membrane domain and a long intracellular part. Palmitoylation targets Cbp/PAG to the 
lipid rafts but this lipid modification is transient, which might allow the presence of 
Cbp/PAG in the membrane only in certain circumstances. A growing body of evidence 
points to Cbp/PAG as a strategic molecule placed at the hub of early signalling, 
involving regulation of SFK, monomeric Ras proteins, and modification of the 
cytoskeleton (reviewed in Svec, 2008). Cbp/PAG binds Csk through phosphorylated 
tyrosine residue 317 (Brdicka et al., 2000; Kawabuchi et al., 2000), and in addition, the 
formation of the Cbp/PAG-Csk complex leads to the activatory conformational change 
within the Csk molecule (Takeuchi, 2000). Several other interactions were discovered 
during the following years. Interestingly, Cbp/PAG indirectly interacts with F-actin, 
through binding of EBP50 (ezrin/radixin/moesin (ERM) binding phosphoprotein) 
(Brdickova et al., 2001). In detail, the C-terminal domain of Cbp/PAG binds the PDY 
domain of EBP50, which further binded to the ERM family of proteins. The interaction 
with ERM proteins in turn linked the Cbp/PAG-EBP50 complex to the actin 
cytoskeleton, which might be an important event to anchor lipid rafts to the actin 
cytoskeleton (Itoh et al., 2002). Interestingly, Cbp/PAG links SFK inhibition with SFK 
polyubiquitylation and degradation (Ingley, 2009).
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1.4.5 Csk in oncogenesis
A line of evidence suggests the role of Csk in neoplastic progression via 
inhibition of SFKs. v-Src was identified as a first oncogene, but activating mutations of 
c-Src are very rare in human cancers. Despite this, Src activity is deregulated in many 
types of cancers, such as in pancreatic neoplasia (Shields et al., 2011). Src activation 
can indeed occur following a loss of regulation at inhibitory Y527 due to loss of Csk, 
altered Csk binding protein function or elevated phosphatase activity. The direct 
involvement of Csk in oncogenesis, however, is not clear (Okada, 2012).
Reduced expression of Csk might play a role in the activation of Src in some 
cancers. In hepatocellular carcinoma, Csk levels are reduced compared to those in 
normal liver tissue and this reduced expression correlates with enhanced Src activity 
(Masaki 1999). Moreover, over-expression of Csk appears to reduce metastatic 
capacitites of human colon cancer cells, accompanied by decreased invasion in Matrigel 
and decreased secretion of MMP2 (Nakagawa et al., 2000).
In the case of pancreatic ductal carcinoma, it has not been well understood 
whether increased Src activity, usually associated with poor prognosis, actually 
contributes to the onset of the disease. A recent study of Shields et al. (2011), with a 
murine model depleted of Csk, showed that Csk deletion accelerated the formation of 
neoplasia only in a Kras context (Shields et al., 2011). Over-expression of Csk in a 
mouse highly metastatic colon cancer cell line NL-17 led to decreased invasion in 
Matrigel and decreased secretion of MMP2 (Nakagawa et al., 2000). Another 
confirmation of the importance of Csk-dependent regulation of SFK activity in cancer
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progression derives from experiments on the human epithelial colon cancer cell lines 
HCT15 and HT29. These two cell lines exhibit elevated autophosphorylation of SFKs 
and reduced expression of Csk in comparison with a highly differentiated 
adenocarcinoma cell line. Introduction of active Csk in both colon cancer cell lines 
reverted their invasiveness in vitro, accompanied by a decrease in SFK activity, an 
increase in E-cadherin mediated cell-cell contacts and a reduction of cell adhesion and 
invasiveness. Moreover, Csk has been shown to have a critical role in defining the cell 
sensitivity to integrin-mediated, adhesion-dependent activation of SFKs (Rengifo-Cam 
et al., 2013).
By contrast, the Csk’s function as a tumour suppressor might depend on the 
expression of its adaptor proteins. A line of evidence supports Cbp/PAG as a potential 
suppressor of SFK-promoted tumour progression. The expression of Cbp/PAG is down- 
regulated in many types of cancer (Oneyama et al., 2008) which might interfere with the 
translocation of Csk to the plasma membrane and efficient control of SFKs. In a recent 
study by Mak et al. (2013), the role of an apoptosis-stimulating protein of p53 (ASPP2)- 
Csk-Src axis in gestional choriocarcinoma has been unveiled. In detail, ASPP2 
messenger RNA (mRNA) is downregulated in choriocarcinoma cell lines and its 
ectopical re-introduction lead to decreased cell migration, specific induction of E- 
cadherin and inactivation of Src; and this specific effect was overcome by silencing of 
Csk (Maket al., 2013).
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CHAPTER 2: Materials and experimental procedures
2.1 General materials
Sodium dodecyl sulphate (SDS), potassium acetate, TRIZMA base, magnesium acetate, 
Tris[Hydroxymethyl]aminomethane (Tris), ethyl- enediaminetetraacetic acid (EDTA), 
KH2PO4 , Na2HPC>4 , NaH2PC>4 , MgSC>4 , bovine serum albumin (BSA), p-glycerol 
phosphate, kanamycin, porcine gelatine, sodium azide, sodium deoxycholate (DOC), 
methyl-p-cyclodextrin, lovastatin, mevalonate, cholesterol, sucrose, rhodamine and 
fluorescein 5- isothiocyanate (TRITC and FITC) were from Sigma-Aldrich (WI, USA). 
NaCl, Na2B4 0 7 , HC1, NaOH, KOH, NaF, NH4 CI, (NH4)S0 4 , acetone, glacial acetic acid, 
ethanol, methanol, trichloroacetic acid (TCA) were from Carlo Erba (Italy). Piperazine- 
1,4-bis (2- ethanesulfonic acid) (PIPES), 4-(2-Hydroxy-ethyl)-piperazine-l-ethane- 
sulfonic acid (HEPES), glycerol, KC1, MgCE, and CaCE were from Merck (Germany). 
Triton-XlOO was from Fluka (Sigma-Aldrich, WI, USA). The broad-range MMP 
inhibitor BB-94 was from British Biotechnology (UK). Other materials will be specified 
under each procedure. All disposable plastic materials were from BD Falcon (NJ, USA). 
Filters (0,45 and 0,2 pm) were from Millipore (MA, USA).
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2.2 Cell culture
2.2.1 Cells and materials
A375MM cells, a characterized human melanoma cell line, were a kind gift of Dr. G. 
Egea (University of Barcellona, Spain). MDA-MB-231 cells, a characterized human 
breast cancer cell line, were obtained from ATCC. Dulbecco’s Modified Eagles 
Medium (DMEM), Dulbecco’s Modified Eagles Medium/F12 medium (DMEM/F12 
1:1) mix, opti-MEM, Foetal Calf Serum (FCS), penicillin-streptomycin (Pen Strep), 
trypsin/EDTA and L-glutamine were all from Gibco (NY, USA).
2.2.2 Growth medium
A375MM were maintained in DMEM/F12 1:1, supplemented with 10% FCS, 4 mM L- 
glutamine, 100 U/ml Pen-Strep. MDA-MB-231 were maintained in DMEM, 
supplemented with 10% FCS, 4 mM L-glutamine, 100 U/ml Pen-Strep.
2.2.3 Growth conditions
Cells were grown in a controlled atmosphere with 5% CO2 at 37 °C in 100 mm Petri 
dishes, up to 80-90% confluence. To propagate A375MM, the medium was removed 
and a PBS/EDTA solution (ImM EDTA in PBS) was added until cells were detached (5 
min). To propagate MDA-MB-231, the medium was removed and a trypsin/EDTA 
solution was added until cells were detached (5-10 min). Cells were then collected in 
medium-containing plastic and centrifuged for 5 min at 300x g. The pellet was 
resuspended in fresh medium and cells were plated.
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2.3 cDNA constructs and amplification
2.3.1 Materials
“Qiagen Plasmid Maxi Kit” was from Qiagen (CA, USA). Luria Broth (LB) powder, 3- 
Morpholino-propane-sulfonic acid (MOPS), RbCl and MnC12 were from Sigma Aldrich 
(WI, USA). Agar was purchased from BD Biosciences (NJ, USA).
Table 2.1. DNA constructs.
wt-Csk wild-type CFP pEGFP-Cl Dr.M.Vielreicher (Wurzburg 
University, Germany)
Csk kinase dead R222K CFP pEGFP-Cl Dr.M.Vielreicher (Wurzburg 
University, Germany)
Lat-Csk R107K,
W47A
OFP-
Myc
pMX Dr.P.Otahal (IMG CAS, Czech 
republic)
Cd25-Csk R107K,
W47A
OFP-
Myc
pMX Dr.P.Otahal (IMG CAS, Czech 
republic)
Lat-Csk-kinase
dead
R107K,
R222K,
W47A
OFP-
Myc
pMX Dr.P.Otahal (IMG CAS, Czech 
republic)
cytosolic Csk R107K,
W47A
OFP-
Myc
pMX Dr.P.Otahal (IMG CAS, Czech 
republic)
PH-PLC wild-type GFP pEGFP-Cl M.Capestrano, PhD (FMNS, 
Italy)
PLD2 wild-type GFP pEGFP-C 1 M.Capestrano, PhD (FMNS, 
Italy)
Syntaxin 2 wild-type GFP pEGFP-C 1 M.Capestrano, PhD (FMNS, 
Italy)
Syntaxin 3 wild-type GFP pEGFP-C 1 M.Capestrano, PhD (FMNS, 
Italy)
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2.3.2 Buffers and media
LB: 25 g/1 LB powder in deionized water and autoclaved for 20 min at 121 °C. LB agar: 
19 g/1 agar in LB and autoclaved for 20 min at 121 °C.
2.3.3 Preparation of competent bacteria
A single colony of DH5a E. Coli bacteria (Stratagene, CA, USA) was picked from an 
LB-agar plate and used to inoculate 10 ml of LB. Bacteria were grown 16 h, the culture 
was diluted in 190 ml of fresh LB and incubated at 37 °C until the optical density 
measured at 600 nm reached 0.5. Bacteria were centrifuged at 4,000 x g  for 10 min at 
4 °C and the pellet resuspended in 64 ml of Tfbl and left on ice for 1-2 h. After 
centrifugation, the pellet was suspended in 8 ml of Tbf2 and cells frozen in liquid 
nitrogen and stored at -80 °C in 400 pi aliquots.
2.3.4 Transformation of bacteria
DNA plasmid (10 ng) was added to 200 pi of competent bacteria (see section 2.3.3) 
thawed on ice. Cells were kept on ice for 30 min followed by a 90 s heat shock at 42 °C. 
800 pi LB were added and cells incubated at 37 °C for 45 min. Bacteria were then 
plated on LB agar containing the appropriate selection antibiotic and incubated for 
further 16 h at 37 °C. The next day, a colony was picked to be inoculated in 2 ml of 
antibiotic-supplemented LB and incubated at 37 °C for 16 h with gentle shaking (200 
rpm). 300 pi of 50% (v/v) sterile glycerol were added to 700 pi of the bacterial 
suspension and stored at -80 °C.
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2.3.5 Large scale preparation of plasmid DNA (Maxiprep)
A small amount of bacteria transformed with the plasmid of interest was scraped away 
from the glycerol stock, inoculated in 2 ml of selection antibiotic- supplemented LB and 
incubated at 37 °C for 8 h. This pre-culture was inoculated in 200 ml of LB containing 
the selection antibiotic and incubated at 37 °C for 16 h. Bacteria were then collected by 
centrifugation at 6,000 x g  in a JA14 rotor for 10 min at 4 °C and processed with the 
“Qiagen Plasmid Maxi Kit” according the manufacturer’s protocol. The DNA obtained 
was resuspended in sterile water and stored at -20 °C until further use.
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2.4 General biochemical procedures
2.4.1 Materials
Ponceau red, ammonium persulphate (APS), N,N,N’,N’- tetramethylethylenediamine 
(TEMED) were from Sigma-Aldrich (WI, USA). 0- mercaptoethanol was from Fluka 
(Sigma-Aldrich, WI, USA). Methanol and glacial acetic acid were from Carlo Erba 
(Italy). Secondary horse-radish peroxidase (HRP)-conjugated antibodies against mouse 
or rabbit IgGs were from Calbiochem (CA, USA). All electrophoresis equipment was 
from Hoefer Scientific Instruments (Germany).
Table 2.2. Antibodies.
Specificity Specie Company Dilution WB Dilution IF
actin rabbit Sigma 1:5000 n/a
Caveolin 1 rabbit Santa Cruz 1:1000 1:300
CD 147 mouse Cell Signalling n/a 1:150
Csk rabbit Santa Cruz 1:1000 1:300
MHC I mouse Biosource n/a 1:50
Myc mouse Sigma 1:1000 1:100
PLD2 rabbit Santa Cruz 1:1000 1:300
p-Cav 1 (Y14) mouse Santa Cruz 1:1000 n/a
p-FAK (Y861) rabbit Santa Cruz 1:1000 n/a
p-Src (Y527) rabbit Invitrogen 1:500 n/a
84
2.4.2 Solutions
Acrylamide stock solution: 30% (w/v) acrylamide-bis acrylamide (Sigma-Aldrich, WI, 
USA). Ten-fold concentrated running and transfer buffer stock solution were from Bio- 
Rad Laboratories (UK). Lysis buffer: if not otherwise indicated, cells were lysed in lx 
sample buffer.
2.4.3 Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis (SDS- 
PAGE)
2.4.3.1 Preparation of polyacrylamide gels
Two 16 x 18 cm plates were used to assemble a polyacrylamide gel. The plates were 
assembled to form a chamber using two 1.5 mm plastic spacers aligned on the lateral 
edges of the plates. The plates were then fixed using two clamps and mounted on a 
bottom-sealing plastic base. The ‘running’ polyacrylamide gel was prepared by mixing
1.5 M Tris-HCl pH 8.8, 10% (w/v) SDS and variable amounts of H2 O and 30% (w/v) 
acrylamide-bisacrylamide solution, to obtain final concentration 375 mM Tris-HCl, 
0.1% (w/v) SDS and the desired percentage of acrylamide, Then, 0.06% (w/v) of APS 
and 0.06% (v/v) TEMED were added to trigger polymerisation, the solution was poured 
into the gap between the plates, leaving about 5 cm for the stacking gel. Immediately 
after pouring, the gel was covered with a layer of deionised water and left at RT for 
about 1 h. The water layer was removed and a 15-well comb was inserted between the 
glasses. The ‘stacking’ polyacrylamide gel was prepared by mixing H2 O, 30% (w/v)
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acrylamide-bisacrylamide solution, 0.5 M Tris-HCl pH 6.8, 10% (w/v) SDS, to obtain
4,5 % (w/v) acrylamide, 125 mM Tris-HCl, 0.1% (w/v) SDS; 0.1% (w/v) ammonium 
persulphate and 0.07% (v/v) TEMED were then added and the poured over the running 
gel and left to polymerize for 1 h at RT.
2.4.3.2 Sample preparation and run
Samples were prepared by addition to cell lysates of SDS-sample buffer, incubation at 
100 °C for 5-15 min in a Multi-Block Heater (Lab-Line, IL, USA), cooled at RT, briefly 
centrifuged and loaded on the gel. One or two wells were loaded with 30 pi of protein 
molecular weight marker solution (GE Healthcare, Amersham Pharmacia Biotech, NJ, 
USA). The gel was then transferred into the electrophoresis apparatus (Hoefer Scientific 
Instruments, NJ, USA) and subjected to a constant current of 7 mA (for 16 h over night 
runs) or 30 mA (for short 4 h runs).
2.4.3.3 Evaluation of protein concentration
When required, protein concentration was evaluated using a commercially available 
protein assay kit (Bio-Rad Laboratories, UK) according to the manufacturer's 
instructions.
2.4.4 Western blotting
2.4.4.1 Protein transfer onto nitrocellulose membrane
Each polyacrylamide gel was soaked for 15 min in transfer buffer, placed on a sheet of
3MM paper (Whatman, NJ, USA) and covered by a nitrocellulose filter (PerkinElmer 
Life and Analytical Sciences, Boston, MA, USA). The filter was covered by a second 
sheet of 3MM blotting paper to form a "sandwich" that was subsequently transferred 
into the blotting apparatus (Hoefer Scientific Instruments, NJ, USA). Protein transfer 
occurred at 500 mA for 4 h or at 125 mA for 16 h. The sandwich was then disassembled 
and the nitrocellulose filter soaked in 0.2% (w/v) ponceau red and 5% (v/v) acetic acid 
for 5 min to stain protein bands, and then washed with 5% acetic acid to remove excess 
unbound dye.
2.4.4.2 Probing nitrocellulose with specific antibodies
The nitrocellulose filters were cut into strips according to appropriate molecular weight 
markers with a scalpel. Strips containing the proteins of interest were incubated in PBS 
containing 5% skim milk powder (Fluka, Sigma-Aldrich, WI, USA) or 5% BSA for 1 h 
at RT, and then with the primary antibody at the appropriate working concentration in 
blocking solution (see Table 2.2. for the working dilutions of antibodies used herein). 
After 1 h incubation at RT, or 16 h incubation at 4 °C, the antibody was removed and 
the strips washed in PBS with 0.05% Triton twice for 10 min. The strips were then 
incubated for 1 h with the appropriate HRP-conjugated secondary antibody diluted 
1:5000 in blocking solution and washed twice in PBS with 0.05% Triton for 10 min and 
once in PBS for 5 min. After washing, the strips were incubated with reagents for 
enhanced chemiluminescence- (ECL) based detection from Amersham Pharmacia 
Biotech (NJ, USA), according to the manufacturer’s instructions and directly exposed to 
BioMax Films (Kodak, NY, USA).
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2.5 Density Gradient
2.5.1 Solutions
TNE buffer: 50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, pH 8.0. Lysis buffer: 1% 
(v/v) TX100 in TNE buffer containing a cocktail of protease inhibitors (Roche).
2.5.2 Optiprep density gradient
The flotation assay on TX 100-insoluble material was performed using previously 
published protocols (Arreaza, Melkonian et al. 1994) with the following modifications. 
Cells (2,5 xlO6) were plated on 100 mm Petri dishes. The day after cells grown to 80% 
confluence were washed in ice-cold PBS and lysed with 1 ml of 1% TX100 in TNE 
buffer for 10 min on ice. Lysates were scraped from dishes, adjusted with OptiPrep 
density gradient medium (a 60% (w/v) solution of iodixanol in water from Sigma- 
Aldrich, Germany) to a final 35%, and then placed at the bottom of a centrifuge tube. A 
discontinuous Optiprep gradient (5-30% in TNE) was layered on top of the lysates and 
the samples were ultracentrifuged at 120,000 x g for 16 h in a swinging- bucket rotor 
(model SW41, Beckman, CA, USA). 1 ml fractions were harvested from the top of the 
gradient.
2.5.3 TCA-based protein precipitation
10% TCA and 0.4 mg/ml DOC were added from a 5X TCA/DOC stock to each fraction. 
The mixture was mixed and incubated on ice for 1 h. After a 10 min centrifugation at 
13,000 x g  at 4 °C, the supernatant was collected and the pellet was washed twice, by
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adding cold acetone, centrifuging as indicated above and removing the supernatant. 
Finally, the pellet was dried under gentle aspiration, resuspended in lxSDS-sample 
buffer, incubated at 100 °C for 5 min and the pH was adjusted by addition of 1M Tris. 
Eventually, the samples were subjected to SDS-PAGE followed by western blot.
2.6 Immunofluorescence microscopy procedures
2.6.1 Materials
Alexa 488-, Alexa 546- and Alexa 633-conjugated phalloidin, goat anti- rabbit, anti­
mouse antibodies were from Molecular Probes (OR, USA) and were used at a final 
dilution 1:300. Paraformaldehyde stock solution (8% aqueous solution) was from 
Electron Microscopy Sciences (PA, USA), and saponin from Sigma-Aldrich (WI, USA). 
Mowiol was from Calbiochem (CA, USA).
2.6.2 List of antibodies used for morphological studies
See Table 2.2 for the working dilutions of antibodies used in immunofluorescence 
experiments.
2.6.3 Solutions
Paraformaldehyde 4% in PBS: 10 ml paraformaldehyde 8%, 2 ml 10-fold concentrated 
PBS stock solution and 8 ml deionized water. Blocking solution: 0.05 % saponin, 0.5 % 
BSA, 50 mM NH4C1 in PBS. Mowiol: 20 mg of mowiol were dissolved in 80 ml of 
PBS, stirred over night and centrifuged for 30 min at 12,000 x g.
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2.6.4 Procedure
Cells were fixed by adding one volume of 4% paraformaldehyde for 15 min at RT, and 
incubated in blocking solution for 30 min at RT. The cells were subsequently incubated 
with the specified antibodies diluted in blocking solution (see Table 2.2 for the list and 
dilutions of antibodies) for 1 h at RT or 16 h at 4 °C. After incubation with the primary 
antibody, cells were washed three times in PBS and incubated with a fluorescent-probe- 
conjugated secondary antibody directed against the constant region of the primary IgG 
molecule for 1 h at RT. Secondary antibodies were diluted 1:300 in blocking solution. 
Alexa 488- and Alexa 546- or 633- conjugated antibodies were used in double-labelling 
(rabbit/mouse) experiments in all possible combinations. Coverslips were mounted in 
mowiol on microscope slides. Immunofluorescence samples were observed with a 
T.I.L.L. Photonics video microscope (T.I.L.L. Photonics, Germany) or a LSM 510 
confocal microscope equipped with 63x objectives (Zeiss, Germany). Optical confocal 
sections were taken at 1 Airy unit with resolution of 512 x 512 pixels and exported as 
TIFF files.
2.7 Gelatine degradation assay
2.7.1 Preparation of fluorophore-conjugated gelatine
This preparation was performed according to Mueller and Chen 1991, with the 
following modifications. 2 mg/ml of porcine gelatine were dissolved in a buffer 
containing 61 mM NaCl and 50mM Na2B4 0 7 (pH 9.3) and incubated at 37 °C for 1 h.
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After this time, 1.8 mg/ml of FITC (or rhodamine) were added and gently mixed for 2 h 
in complete darkness. This preparation was then dialysed 16 h at RT in PBS in complete 
darkness. Dialysis was usually continued for 2 days with 2-3 buffer changes per day. 
After a quick spin to remove insoluble material, small aliquots, containing 2% (w/v) 
sucrose, were stored in the dark at 4 °C.
2.7.2 Preparation of fluorophore-conjugated gelatine-coated coverslips
Fluorescent gelatine coated coverslips were prepared and the assay carried out as 
described (Mueller and Chen 1991; Baldassarre, Pompeo et al. 2003). Briefly, glass 
coverslips were sterilized in 70% ethanol for 15 min at RT. Air-dried coverslips were 
then coated with pre-warmed fluorophore-conjugated gelatine, using enough to cover 
the surface. Each coverslip was inverted onto a 100 pi drop of 0.5% ice-cold 
glutaraldehyde in PBS and incubated on ice for 15 min. Each coverslip was then 
transferred to each well of a standard 12-well plate with the gelatine-coated side up, 
gently washed three times with PBS and finally incubated with sodium borohydride (5 
mg/ml) in PBS for 3 min at RT. Washed coverslips were sterilized again in 70% ethanol 
for 5 min, dried for 5 min under a sterile hood and then quenched in complete cell 
medium for 1 h at 37 °C. Coverslips were thus ready for seeding cells.
2.7.3 ECM degradation assay
The ECM degradation assay was performed according to the previously published 
protocol, referred to as invadopodia synchronization protocol. Briefly, cells were plated 
on gelatine-coated coverslips with 5 pM BB94. After 16 h, BB94 was washed out to
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allow synchronous invadopodia formation and cells were fixed at 3 h and processed for 
immunofluorescence as described above. Most experiments were analyzed with the 63x 
oil-immersion objective of a T.I.L.L. Photonics video microscope, considering at least 
30 random fields (containing about 100 cells). TIFF-formatted images were thresholded 
to remove noise and enhance the contrast of structures of interest. Areas of degradation 
to the total area for each condition was then normalized for cell number and expressed 
as a arbitrary units. Each experiment was repeated at least three times.
2.8 Cell treatments
2.8.1 Lipid-mediated transfection
Cells were plated at 50% confluence. The day after 0.45 pg/cm2 DNA and 2 pl/pg 
TransFast (Promega, WI, USA) in medium without FCS were added for 1 h at 37 °C. 
Complete medium was then added. Experiments to evaluate the effects of transfection 
were performed at least 16 h later.
2.8.2 Retroviral transfection
Retroviruses (RV) were prepared by transfection of Phoenix- Ampho cells (Origene, 
Rockville, MD) with plasmid DNA using Lipofectamine 2000 (Invitrogen, Karlsbad, 
CA) in six-well plates. RV- containing supernatant was centrifuged to remove debris 
and then used to spin-infect (1200*g/90 min at room temperature) A375MM and MDA- 
MB-231 in the presence of Polybrene (10 pg/ml, Sigma-Aldrich, St. Loius, MO). Cells
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were allowed to expand in culture and then were sorted using FA Vantage cell sorter 
(BD Biosciences, San Jose, CA) to isolate infected OFP+ cells.
2.8.3 RNA interference (RNAi)
2.8.3.1 Materials
Smart pool reagents for human Csk, Seladinl/DHCR24 and PLD2 were purchased from 
Sigma (CA, USA). Stock solutions were aliquoted and stored at -20 °C. siRNAs were 
employed at the final concentration of 100 nM. Lipofectamine 2000 was from 
Invitrogen (CA, USA).
2.8.3.2.Procedures
To perform RNAi, cells (2><105) were seeded in 12 well plates. The following day a 
solution A (10 pi of an siRNA solution plus 90 pi of opti-MEM) and a solution B (1 pi 
of Lipofectamine 2000 plus 100 pi of opti-MEM) were prepared. After 5 min A and B 
were mixed and incubated for 20 min at RT. 200 pi of the mix were added to cells in 
800 pi of complete medium without ATB. Silencing was evaluated by western blot (see 
section 2.4.4) 96 h after transfection. To perform degradation assays (see paragraph 
2.7.3) cells were plated on gelatine-coated coverslips 72 h after siRNA treatment. For 
rescue experiments, transient expression of the DNA plasmid of interest was performed 
72 h after siRNA treatment.
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2.8.4 Cholesterol manipulation
2.8.4.1 Depletion procedure
Cholesterol depletion was performed as previously published (Keller and Simons 1998) 
with some modifications. To evaluate the effect of cholesterol depletion on gelatine 
degradation, cells were seeded on gelatine-coated coverslips. Once attached, fresh 
complete medium was added in the presence or absence of 4 pM lovastatin and 0.25 
mM mevalonate. After 16 h, cells were treated or not with 10 mM methyl-P- 
cyclodextrin in FCS-free medium for 30 min. Methyl-p-cyclodextrin was washed-out 
with fresh complete medium and cells fixed after 3 h. Control and treated cells were 
processed for immunofluorescence microscopy (see section 2.6). To test the 
consequence of cholesterol depletion on invadopodia biogenesis we associated this 
procedure to the use of the invadopodia synchronization protocol (see paragraph 2.7.3). 
In detail cells were plated on gelatine-coated coverslips with BB94. The inhibitor was 
kept during the entire cholesterol depletion procedure and washed-out following cell 
treatment with methyl-p-cyclodextrin. Cells were replenished with fresh complete 
medium, fixed after 3 h and assayed for ECM degradation.
2.8.4.2 Re-addition procedure
Cholesterol re-addition was performed as previously published (Furuchi and Anderson 
1998) with some modifications. 20 pi of cholesterol (20 mg/ml in ethanol) were 
solubilized in 10 ml of DMEM/F12 1:1 containing 1% methyl-p-cyclodextrin, while 
mixing at 40 °C to achieve a final 0,04 mg/ml cholesterol concentration. One ml of this
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cholesterol/methyl-p-cyclodextrin mix was added for lh at 37 °C to cells plated on 
gelatine-coated coverslips with BB94 soon after cholesterol-depletion. BB94 was then 
washed out with complete medium and cells fixed after 3 h. Control and cholesterol- 
depleted and-replenished cells were assayed for ECM degradation as reported above.
2.8.4.3 Triparanol treatment
To evaluate the effect of inhibiting of DHCR24 by Triparanol on gelatine degradation, 
cells were seeded on gelatine- coated coverslips. Once attached, fresh complete medium 
was added in the presence or absence of 4 pM lovastatin and 0.25 mM mevalonate. 
After 16 h, cells were treated or not with 3-10 pM Triparanol in dFCS-medium for 4 h. 
BB94 was washed out and FCS-containing medium with 3-10 pM Triparanol was 
added. Control and treated cells were fixed after 3 h (A375MM) or 1 h (MDA-MB-231) 
and processed for immunofluorescence microscopy (see section 2.6).
2.8.4.4 24(S), 25-epoxycholesterol treatment
To evaluate the effect of inhibiting of DHCR24 by 24(S), 25-epoxycholesterol (EC) on 
gelatine degradation, cells were seeded on gelatine-coated coverslips. Once attached, 
fresh complete medium was added in the presence or absence of 4 pM lovastatin and 
0.25 mM mevalonate. After 16 h, cells were treated or not with 10 pM EC in dFCS- 
medium for 4 h. BB94 was washed out and FCS-containing medium with 10 pM (EC) 
was added. Control and treated cells were fixed after 3 h (A375MM) or 1 h (MDA-MB- 
231) and processed for immunofluorescence microscopy (see section 2.6).
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2.8.5 Transport assays: antibody uptake and recycling
2.8.5.1 Materials
See table 2.2.
2.8.5.2 Antibody recycling assay
To assess internalisation and recycling of the major histocompability complex 1 
(MHC1) and CD 147 antibody, the following procedure was followed: The cells were 
initially subjected to binding of MHC1 antibody or Alexa 546-transferrin to the plasma 
membrane, as reported here: the cells were and incubated with 1 mg/ml monoclonal 
antibody against human MHC class 1 or CD147 for 30 min at 37 °C. The cells were 
then washed three times with low pH buffer (acid wash) to remove the unbound 
antibody. For the uptake assay, upon the previous binding step, the cells were incubated 
in prewarmed (37 °C) complete medium for varying times, to allow the specific 
antibody internalisation.
2.8.6 Wound healing assay
To perform wound healing assay, silicone Culture Inserts were used that create two cell 
culture reservoirs divided by thick wall. In each reservoir, 6x104 cells were plated in 
final volume 100 pi. After 16 h, Culture Inserts were carefully removed with a tweezer 
and the cells were washed 3 times with fresh medium. The images were taken of control 
and treated cells at indicated times up to 24 h.
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Statistics
All data in the text and figures are expressed as mean (SEM) and 2-way analysis of 
variance statistical analyses were carried out with Excel Student’s t-test. A P value of 
less than 0.05 was considered significant (*P < 0.05, **P < 0.01, ***P < 0.001).
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CHAPTER 3: Regulation of cholesterol homeostasis at
invadopodia
3.1 Introduction
There are many indications suggesting that invadopodia present the features of, 
or are enriched in, cholesterol-enriched microdomains, also known as lipid rafts. Local 
actin polymerization, mediated by the Arp2/3 complex, is required for invadopodia 
initiation and assembly of invadopodial core actin structure (Yamaguchi et al., 2005). 
And indeed, it has recently been suggested that lipid rafts are preferential sites for N- 
WASP Arp2/3 dependent actin polymerization, possibly because of efficient 
recruitment of these actin nucleators (Golub and Caroni, 2005). Also, the majority of 
the MT1-MMP, a protease crucial for focal matrix degradation at invadopodia, has been 
shown to be preferentially sorted to lipid rafts (Mazzone et al., 2004).
In our laboratory, we have previously shown that invadopodia formation and 
efficient ECM degradation depends on appropriate levels of cholesterol at the cell 
surface. Moreover, we have demonstrated a pivotal role of caveolin in the regulation of 
cholesterol homeostasis at invadopodia in A375 melanoma cells (Caldieri et al., 2009). 
Another report has confirmed the importance of cholesterol and caveolin 1 in MDA- 
MB-231 breast cancer cells (Yamaguchi et al., 2009).
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To further analyze the lipid raft features of invadopodia, I investigated the role 
of a specific downstream cholesterol biosynthesis enzyme, Seladinl/DHCR24, on 
invadopodia formation, random migration and eventually recycling of plasma 
membrane proteins.
3.2 Results
3.2.1 Exchange of cholesterol for desmosterol
Desmosterol is a cholesterol biosynthesis intermediate form that differs 
from cholesterol only in a double bond at carbon 24 (C24). Desmosterol, when 
exchanged for cholesterol, supports normal functions in cell growth and viability. 
However, desmosterol has lower affinity for lipid rafts and fails to support lipid raft- 
dependent signalling as effectively as cholesterol (Vainio et al., 2005), as documented 
in a report on insulin receptor lipid raft association and activation (Sanchez-Wandelmer 
et al., 2009). Therefore, it could be a useful tool for perturbing these specific membrane 
domains. I applied a modification of a published protocol based on the use of methyl-(3- 
cyclodextrin (M|3CD) to extract plasma membrane cholesterol. From the chemical point 
of view, cyclodextrins are composed of seven glucose units. The unique property of 
M|3CD (and other cyclodextrins) results from its characteristic cylindrical structure with 
a hydrophilic surface and hydrophobic cavity (Betzel et al., 1984), that is capable of 
accommodating lipophilic molecules, such as cholesterol, by formation of an inclusion
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Fig. 3.1. Biosynthesis of cholesterol. A) The schematic model of 
branched pathway of mevalonate metabolism in mammalian cells. B) 
The post-lanosterol steps of cholesterol synthesis in mammalian cells. 
The biosynthesis of cholesterol can proceed either through the Bloch 
pathway (left) or Kandutsch-Russell pathway (right). Hypothetically, 
the C24 double bond can be reduced at each stage by Seladin 
1/DHCR24.
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complex. As the intracellular pool of cholesterol can continuously replenish plasma 
membrane cholesterol, extraction by MpCD was preceded by a treatment with 
lovastatin, one of the commercially available cholesterol lowering drugs statins, potent 
inhibitors of HMG-CoA reductase. HMG-CoA reductase is a rate-limiting enzyme of 
the mevalonate pathway of cholesterol biosynthesis. In my experiments, mevalonate 
was used as well, to minimize the side effects on production of the isoprenoid 
precursors (Brown and Goldstein, 1980), the non-sterol products of the mevalonate 
pathway (Fig. 3.1 A).
Cholesterol is the key lipid component of lipid rafts and the extraction of 
cholesterol from the plasma membrane results in the dispersion of such domains. In a 
first experimental set, I combined the depletion of cholesterol by M|3CD with a re­
addition of a saturated complex of M(3CD and cholesterol or desmosterol in the 
degradation assay on adherent cells plated on fluorophore-conjugated gelatine in the 
presence of broad spectrum inhibitor of metalloproteases batistamat (BB94). Tumour 
cells plated on the appropriate substrate, such as gelatine, form spontaneously 
degradation-competent invadopodia, in some cases right after attachment, well before 
the spreading process is completed. This represents technical and interpretative 
problems when applying experimental approaches that require longer pre-treatment 
times. One would ideally wish to uncouple cell attachment and spreading from 
invadopodia formation. To solve this issue, I took advantage of a degradation assay 
protocol previously set up in my laboratory to allow synchronous formation of 
invadopodia. This approach makes use of broad-spectrum metalloprotease inhibitor
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BB94 which functions reversibly and competitively by occupying the active site of the 
enzyme and reversibly blocks invadopodia formation without affecting cell behaviour in 
any other aspect. Cells are plated and the desired treatment is applied in the presence of 
BB94, hence cells are not allowed to form invadopodia and degrade the ECM during 
the pre-treatment. BB94 is then washed out and cells are allowed to degrade the ECM 
for appropriate times depending on the cell type (Ayala et al., 2008). After the treatment, 
I assayed the ability of cells to degrade the ECM after BB94 wash out. As we have 
strong evidence that invadopodia have features of lipid rafts, I would have expected 
cholesterol but not desmosterol to rescue the M(3CD-induced phenotype. Surprisingly, I 
observed that both desmosterol and cholesterol were able to do so (Fig. 3.2). This might 
be due to the fact that desmosterol is an intermediate of cholesterol metabolism and can 
be converted rapidly into cholesterol via the reaction catalysed by the ubiquitous 
enzyme 24-dehydroxysterol reductase (DHCR24), that catalyses the reduction of the 
delta-24 double bond of sterol intermediates during cholesterol biosynthesis (Fig. 3.1 B).
Initially identified as a gene down-regulated in Alzheimer’s disease vulnerable 
brain regions, DHCR24 was initially named Selective Alzheimer’s disease Indicator 1 
(Seladin 1) (Greeve et al., 2000). Moreover, missense mutations of Seladin 1/DHCR24 
have been reported to cause desmosterolosis, a rare autosomal recessive disorder 
biochemically characterized by elevated plasma levels of desmosterol and accumulation 
of desmosterol in the plasma membrane. In vitro, only desmosterol was present in 
untreated J774 murine macrophage-like cells that are defective in Seladin 1/DHCR24 
(Zerenturk et al., 2011).
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I thus reasoned that inhibition of DHCR24 was essential to better understand the 
effects of desmosterol in my experimental conditions.
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Fig. 3.2. Cholesterol depletion blocks invadopodia formation.
A375MM cells were plated on gelatine in the presence of BB94 
and the lovastatin/mevalonate mix (L+M), and were left untreated 
or subjected to acute cholesterol extraction with MCD (MCD) 30 
minutes prior to BB94 washout. Samples were fixed after 3 hours. 
Quantification of ECM degradation revealed an 80% decrease in 
MCD-treated as compared to lovastatin/mevalonate-treated cells. 
Both cholesterol and desmosterol readdition to depleted cells prior 
to BB94 washout restored the normal phenotype. Error bars are 
standard deviations of the mean. Three independent experiments 
were performed.**/5 < 0.01, ***/>< 0.001.
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3.2.2 Inhibition of Seladinl/DHCR24 1 by Triparanol
Therefore, I explored strategies to inhibit Seladin 1/DHCR24 to achieve 
accumulation of desmosterol at the expense of cholesterol. My first choice was an 
inhibitor of DHCR24 commercially available under the name Triparanol, which inhibits 
DHCR24 in non-competitive fashion (Bae and Paik, 1997). Triparanol is not widely 
used but few studies convincingly described its effects on desmosterol accumulation 
due to DHCR24 inhibition. Functionally, in 3T3-L1 adipocytes, Triparanol disrupts 
caveolae-dependent insulin-receptor signalling and co-incubation with cholesterol 
rescued IR signalling to the control values (Sanchez-Wandelmer et al., 2009).
I plated the A375MM cells on gelatine coverslips in the presence of lovastatin, 
mevalonate and BB94. The next day, I pre-treated the cells with Triparanol at 
concentrations ranging from 3 fiM to 10 pM. After 4 h, I added cholesterol to the cells 
in the complex with M|3CD in serum free medium in the presence of BB94 and 
Triparanol. After 1 h, I washed out BB94 and allowed the cells to degrade the matrix for 
3 h in complete medium, in the continuous presence of Triparanol. As A375MM cells 
treated with higher concentrations of Triparanol were not viable after addition of 
cholesterol, only experiments after pre-treatment with 3 |iM Triparanol were quantified. 
Clearly, even this lower concentration of inhibitor was sufficient to block gelatine 
degradation and its effect was overcome by cholesterol addition, validating the 
specificity of the Triparanol effect (Fig. 3.3 A).
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Fig. 3.3. Inhibition of Seladinl/DHCR24 blocks ECM 
degradation. A375MM cells were plated on gelatine in the 
presence of BB94 and the lovastatin/mevalonate mix (mock), and 
were left untreated or subjected to A) Triparanol or B) 24(S),25- 
epoxycholesterol treatment (EC) (B) treatment for 4 h prior to 
BB94 wash out. Cholesterol was re-added in saturated complexes 
with MCD to the treated cells (Choi). Cells were fixed after 3 h and 
ECM degradation quantified. Error bars are standard deviations of 
the mean. Three independent experiments were performed. P < 
0 .001 .
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3.2.3 Inhibition of Seladinl/DHCR24 by 24(S), 25-epoxycholesterol
According to the so-called “Oxysterol Hypothesis of Cholesterol Homeostasis”, 
which was first formulated by Kandutsch and colleagues in 1978 (Kandutsch et al., 
1978), the suppressive effect of cholesterol synthesis might be mediated by 
endogenously produced oxysterols. Among the many oxysterols 24(S), 25- 
epoxycholesterol (24(S), 25-epoxy-cholest-5-en-3b-ol; 24,25-EC for brevity EC from 
here on) is unique because it is synthesised via a shunt of the mevalonate pathway of 
cholesterol biosynthesis in cholesterogenic cells rather than being derived from 
cholesterol like the other oxysterols. The likely physiological role of EC is to control 
cholesterol homeostasis at different levels.
Interestingly, EC has recently been shown to inhibit Seladin 1/DHCR24, causing 
an increase in desmosterol levels at the expense of cholesterol (Zerenturk et al., 2011). 
Based on this knowledge, I decided to use EC to confirm the role of cholesterol and 
more specifically the role of Seladin 1/DHCR24 in the invasive behaviour of tumour cell 
lines. As in the previous experiment, I plated A375MM cells on fluorophore-conjugated 
gelatine coverslips in the presence of BB94 and incubated them with a mixture of 
lovastatin and mevalonate overnight.
The next day, I pre-treated cells with 10 pM EC for 4 hours prior to the addition 
of a saturated MpCD/cholesterol complex. Four hours after re-addition, I washed out 
BB94 and allowed the cells to degrade for 3 h. I fixed the cells and quantified the 
degradation. I observed that gelatine degradation inhibited by EC, was rescued by 
cholesterol replenishment. As in the case of Triparanol, the phenotype rescue suggests
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the specificity of the effect on EC and confirms that inhibition of ECM degradation was 
due to lack of cholesterol (Fig. 3.3B).
3.2.4 Inhibition of Seladinl/DHCR24 in an alternative cell model
In parallel, and to help validate my findings, I applied the same approaches to an 
additional cell model, the breast cancer cell line MDA-MB-231, with some minor 
modifications. I observed that MDA-MB-231 cells, unlike A375MM cells, are viable 
even in the presence of higher concentration of Triparanol (10 pM). I applied the same 
protocol as described above, only with shorter degradation times of 1,5 h. I confirmed 
the same effect of both inhibitors on ECM degradation (Fig. 3.4).
Next, I explored the consequences of Seladin 1/DHCR24 inhibition on the 
migration of MDA-MB-231 cells, since the role of lipid rafts in migration is clearly 
established. Cell migration is a multistep, highly integrated process, which is key for the 
invasion of tumour cells. Directional migration can be measured in the so-called wound 
healing assay. Cells were plated in silicone inserts, called Culture Inserts, with defined 
cell-free gap, and incubated overnight in the presence of lovastatin and mevalonate. The 
next day, the inserts were removed and the confluent cells were allowed to migrate and 
close the gap between two cells patches for 16 h in the presence of 10 pM Triparanol or 
10 pM EC (thus the same concentration as above in the degradation assay) (Fig. 3.5 A). 
The characteristic parameter in this assay is the change in the cell-covered area, over
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time. Both inhibitors block migration significantly by 50 per cent, suggesting a role of 
Seladin 1/DHCR24 in migration of tumour cells (Fig. 3.5 B).
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Fig. 3.4. Inhibition of Seladinl/DHCR24 blocks ECM 
degradation. MDA-MB-231 cells were plated on gelatine in the 
presence of BB94 and the lovastatin/mevalonate mix (mock), and 
were left untreated or subjected to A) Triparanol or B) 24(S),25- 
epoxycholesterol treatment (EC) (B) treatment for 4 h prior to 
BB94 wash out. Cholesterol was re-added in saturated complexes 
with MCD to the treated cells (Choi). Cells were fixed after 1 h and 
ECM degradation quantified. Error bars are standard deviations of 
the mean. Three independent experiments were performed. **P < 
0 .01 , * * * / > <  0 .001 .
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Fig. 3.5. Inhibition of Seladin 1/DHCR24 by Triparanol and 
24,25-epoxycholesterol inhibits the gap closure in wound 
healing assay. MDA-MB-231 cells were plated in the culture 
inserts in the presence of the lovastatin/mevalonate mix (mock), 
and were left untreated or subjected to Triparanol or 24(S),25- 
epoxycholesterol (EC) treatment for 4 h prior to the insert removal. 
Cells were fixed after 16 h and ECM degradation quantified. Error 
bars are standard deviations of the mean. Three independent 
experiments were performed. P < 0.01.
3.3 Discussion
Invadopodia are platforms where signalling events, membrane traffic and actin 
remodelling integrate towards the efficient focal degradation of the ECM. It has been 
previously shown that invadopodia formation and efficient ECM degradation depends 
on appropriate levels of cholesterol at the cell surface (Caldieri et al., 2009; Yamaguchi 
et al., 2009). The evidence that cholesterol homeostasis is essential for invadopodia 
formation suggests a tight control of cholesterol homeostasis in invadopodia-forming 
cells.
I took advantage of the regulator of the ultimate step of cholesterol synthesis, 
Seladin 1/DHCR24, which catalyzes the conversion of desmosterol to cholesterol. 
Emerging studies have suggested that desmosterol is not able to fully substitute 
cholesterol in the lipid rafts. Indeed, it is documented that loss of Seladin 1/DHCR24 
impaired lipid raft-dependent signalling events due to the accumulation of membrane 
desmosterol.
I also tested the Seladin 1/DHCR24 substrate desmosterol to gain further insight 
into the cholesterol-dependence of invadopodia. To achieve this, I used two known 
inhibitors of Seladin 1/DHCR24, Triparanol and EC. The latter one is a potent oxysterol 
regulator, which is known to regulate cholesterol levels via multiple ways. Importantly, 
it has been shown that EC shuts down cholesterol synthesis at Seladin 1/DHCR24 
without affecting its protein levels (Zerenturk et al., 2011).
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I showed that in the both cell lines, A375MM and MDA-MB-231, Triparanol 
and EC caused decrease in gelatine degradation. This effect was further abolished by 
addition of cholesterol, which also confirmed the specificity of the effect of 
Seladin 1/DHCR24 inhibitors. Consequently, in MDA-MB-231 cells inhibition of 
Seladin 1/DHCR24 slowed down random migration.
The cholesterol-synthesis enzyme Seladin 1/DHCR24 is not widely studied in 
the context of cancerogenesis but a few studies have implied its role in the prostate 
cancer (Battista et al., 2010; Bonaccorsi et al., 2008; Hendriksen et al.; 2006). The level 
of Seladin 1/DHCR24 expression is a hallmark of prostate cancer, with the levels 
inversely correlating with grade of prostate cancer. Moreover, decreased gene 
expression has been connected to the elevation of metastasis incidence. This gene 
down-regulation is further linked to increase in androgen secretion and cell proliferation.
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CHAPTER 4: Regulation of Src family of tyrosine kinase 
(SFK) activity at invadopodia
4.1 Introduction
The importance of SFK-derived signalling in invadopodia formation has been 
repeatedly demonstrated through a variety of approaches including RNA interference, 
expression of mutants and the use of inhibitors. Nevertheless, there is less known about 
regulation of SFK. Among the plethora of SFK substrates, tyrosine phosphorylated 
Caveolin 1 acts inhibitory towards invadopodia formation (Caldieri et al., 2009). SFK- 
dependent tyrosine 14 phosphorylation of Caveolin 1 forms a docking site for C- 
terminal Src kinase (Csk), thus recruiting it from the cytosol to the cholesterol-rich lipid 
rafts in the plasma membrane to exert its function. Csk specifically phosphorylates the 
C-terminus tail inhibitory tyrosine (Y527 in Src) of the non-receptor SFKs, thereby 
inhibiting their activity (Ingley, 2008). Csk is ubiquitously expressed and shares 40 per 
cent sequence identity with SFKs, with a similar domain structure but lacking any N- 
terminal fatty acid modification. Unlike SFKs, Csk is not phosphorylated on activating 
or inhibitory sites in line with the notion that Csk is regulated sterically rather than 
catalytically. The mechanism underlying cell membrane localization of Csk has been 
investigated and has led to the identification of lipid raft-associated adaptor proteins 
(Ingley, 2009), including the phosphoproteins Cbp/PAG (Kawabuchi et al., 2000),
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LIME (Brdickova et al., 2003) and Caveolin 1 (Cao, 2002). Thus, I investigated the role 
of Csk and effect of its membrane localization at the degradation capability of 
invadopodia.
4.2 Results
4.2.1 Csk knock-down stimulates invadopodia formation
In our laboratory, we have previously shown that Y14-phosphorylated caveolin 
1 is inhibitory towards invadopodia biogenesis and we hypothesized that this was 
probably by removing cholesterol from the plasma membrane and possibly via 
inhibition of SFK-dependent signalling (Caldieri et al., 2009). Indeed, the pY14 of 
caveolin 1 serves as a docking site for the SH2 domain of Csk (Cao, 2002), the 
endogenous SFK inhibitor (Ingley, 2008). Hence, I directly explored the function of 
Csk in invadopodia formation and function. Csk specifically phosphorylates the 
inhibitory tail tyrosine of SFKs (Y530 in human Src) and thus inhibits their activity. 
72 h after siRNA treatment, Csk-depleted A375MM cells or MDA-MB-231 cells (Csk- 
KD) were plated on FITC-conjugated gelatine in presence of BB94 to block 
invadopodia formation. The following day, a degradation assay was performed. Csk 
was knocked-down with more than 60 per cent efficiency (Fig. 4.1 A) leading to a more 
than two-fold increase in the degradation per cell in A375MM melanoma cells and 
MDA-MB-231 breast cancer cells (Fig. 4.1 B). In parallel, 72 h after siRNA treatment,
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Csk-depleted A375MM cells were plated on gelatine in the presence of BB94 to block 
invadopodia formation. The following day, BB94 was washed out to allow invadopodia 
formation and after 5 h cells were lysed in 1 x sample buffer and subjected to Western 
blotting. Membranes were stained with antibodies against Csk to reveal the level of 
knock-down and against phosphorylated inhibitory tyrosine of Src (Y530) and Src- 
substrate phospho-FAK (Y421) (Fig. 4.2 A). After the Csk knock-down, I observed 
lower levels of inhibited Src and increased phosphorylation of the prominent SFK 
substrate FAK (Fig. 4.2 B). This would suggest that the role of Csk in invadopodia 
biogenesis is dependent on its catalytic activity. To further confirm this conclusion, I 
performed phenotype rescue after siRNA-mediated knock-down of Csk by over­
expressing wild-type and kinase dead Csk. The Csk kinase dead mutant bears a K 222 
to-R mutation that makes it kinase defective. Indeed, only wt-Csk efficiently decreased 
the level of ECM degradation of siRNA-treated cells to mock levels (Fig.4.3).
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Fig. 4.1. Csk-knock down affects ECM degradation. A)
Efficiency of Csk knock-down. A375MM and MDA-MB-231 cells 
were treated without (mock) or with (RNAi) siRNA targeting Csk 
for 96 hours. RNAi reduced Csk expression up to 70% as shown in 
western blots of lysates using antibodies against Csk and actin as a 
loading control. B) Quantification of ECM degradation revealed an 
almost three-fold increase in degradation per cell in A3 75MM and 
MDA-MB-231 Csk knock-down cells compared to mock- 
transfected (mock). Error bars represent standard deviation of the 
mean. Three independent experiments were performed. P < 0.001.
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Fig. 4.2. Src-dependent phosphorylation after Csk knock­
down.
A3 75MM cells on gelatine were treated without (mock) or with 
(RNAi) siRNA targeting Csk for 96 hours. Image shows western 
blots of lysates using antibodies against Csk, pSrc (Y527), pFAK 
(Y861) and actin as a loading control. B) After 96 hours of siRNA 
treatment cells were lysed and subjected to Western blotting. 
Membranes were stained with antibodies against Csk to reveal the 
level of knock-down and against pSrc (Y527) and pFAK (Y861).
The ablation of Csk resulted in decreased phosphorylation of 
inhibitory tyrosine of Src and increased phosphorylation of FAK. 
Error bars represent standard deviation of the mean. Three 
independent experiments were performed. **P < 0.01, ***p < \ \$  
0.001.
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Fig. 4.3. Csk knock-down stimulates invadopodia formation 
and the phenotype is efficiently rescued upon wt Csk 
overexpression. Quantification of ECM degradation revealed a 
150 per cent increase in Csk knock-down A375MM cells (siRNA) 
compared to mock-transfected cells (mock). The phenotype was 
efficiently rescued by overexpression of wild type Csk (Csk wt) 
but not catalytically inactive kinase dead Csk (Csk KD). Error bars 
represent standard deviation of the mean. Three independent 
experiments were performed. **P < 0.01, ***P < 0.001.
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4.2.2 Csk is not involved in EGF stimulation
Invadopodia formation has been shown to be initiated by EGF that in turn leads 
to activation of the actin polymerization machinery (Yamaguchi et al., 2005). The 
importance of EGF signalling for invadopodia biogenesis is not very clear, since 
invadopodia formation in many cell models does not necessarily require EGF receptor 
(EGFR) activation. It is well established that EGF binding activates c-Src (Biscardi et 
al., 1999a; Biscardi et al., 1999b), which then phosphorylates Tyr 845 of EGFR to 
enhance the EGF-dependent response. It has been suggested that also Csk might have a 
role in EGF signalling. Upon EGF stimulation of Cos-1 cells, Csk is transiently 
translocated to SFK-phosphorylated Cbp in the membrane ruffles. This connection 
leads to downregulation of SFK in the early stage of EGF signalling ( Matsuoka, 2003). 
Over-expression of Csk catalytic mutants has been used as a tool to inactivate SFKs in a 
study on the effect of EGF-dependent migration of human pancreatic carcinoma cells. 
Expression of wt- but not kinase dead Csk disrupted the EGF-induced activation of 
SFKs and cell migration on vitronectin (Ricono et al., 2009). Moreover, EGF-dependent 
signalling in breast cancer cell lines has a biphasic character. At low concentration, EGF 
activates SFKs by Y416 phosphorylation, whereas higher concentration suppresses their 
activity via inhibitory tyrosine phosphorylation (Y527). Based on this evidence, I 
decided to explore the function of Csk in EGF stimulation of MDA-MB-231 cells. I 
performed RNAi of Csk as described above and after 72 h I plated the mock and Csk- 
KD cells on transparent-gelatine coated wells in FCS-free medium. The next day, I 
stimulated the starved cells with EGF for indicated time (0, 5 and 30). I lysed the cells 
in sample buffer and performed Western blot analysis. I probed the membranes with
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anti-p-Erk 1/2 antibody. Erk 1/2 are down-stream effectors of EGFR, therefore 
phosphorylation Erk 1/2 is a reliable indicator of stimulation of EGFR-MAPK/Erk 
pathway. I reported no difference between stimulation of Erk 1/2 in mock and Csk- 
knock down cells, suggesting that Csk has no role in EGF signalling in our cell system 
(Fig. 4.4).
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Fig. 4.4. Csk is not involved in EGF stimulation. MDA-MB-231 
cells on gelatine were treated without (mock) or with (RNAi) 
siRNA targeting Csk for 96 hours. Image (A) shows western blots 
of lysates using antibodies against Csk, pERK and actin as a 
loading control. B) Levels of pErk after 5 min and 30 min of EGF 
stimulation. Error bars represent standard deviation of the mean. 
Two independent experiments were performed. No significant 
difference between mock and RNAi cells was reported.
4.2.3 Csk chimaeras with different membrane anchors
I showed in the previous chapter that acting on cholesterol biosynthesis by 
blocking the specific reductase DHCR24 leads to inhibition of ECM degradation and 
migration of tumour cells. I reasoned that if invadopodia are enriched in lipid rafts 
(Caldieri et al., 2009; Yamaguchi et ah, 2009) and Csk is inhibitory towards their 
formation and function, then targeting Csk specifically to lipid rafts could directly affect 
ECM degradation.
To find out how targeting of Csk to different membrane compartments affects 
ECM degradation, through collaboration with Dr. Tomas Brdicka (IMG, AS, Prague) I 
obtained C-terminally modified Csk constructs with distinct targeting motifs. These 
constructs code for fusion proteins containing a membrane-specific targeting sequence, 
constitutively active Csk, a Myc tag and orange fluorescent protein (OFP). Lipid raft- 
targeted kinase-dead Csk and cytosolic Csk were included as controls (Fig. 4.5). To 
minimize possible complicating effects of interactions of Csk Src-homology domains 2 
and 3 (SH2 and SH3) with other proteins, such as adaptor proteins and substrates, Csk 
was mutated to inactivate these domains (R107K mutation to inactivate the SH2 domain 
and W47A to inactivate the SH3 domain) (Otahal et al., 2011).
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4.2.4 Effect of transient transfection of Csk chimaeras on ECM degradation
I started with a transient transfection approach. All the constructs are cloned into 
the pMXs retroviral vector, thus primarily designed for the introduction in the cells via 
retroviral transfection but they are also amenable to standard lipid-mediated transient 
transfection protocols. For this reason, I adjusted the method used in our laboratory by 
using higher amounts of plasmid DNA than usual. In this way I was able to achieve a 
level of transfection of A375MM cells that allowed me to perform immunofluorescence 
but not biochemical analysis. I was not successful with MDA-MB-231 cells as they are 
more difficult to transfect 'and did not obtain levels of transfection high enough to 
perform experiments with a sufficient number of cells.
In my transient transfection experiments, I observed that lipid-raft targeted Csk 
(Lat-Csk), but not the other forms, inhibited ECM degradation in A375MM cells. This 
is in accord both with my findings on the inhibitory effect of Csk on invadopodia 
function and with our previous results suggesting that invadopodia organize into 
cholesterol-enriched lipid raft domains.
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4.2.5 Retrovirus-mediated transfection of Csk chimaeras
After the observation in transiently transfected A375MM cells I decided to 
follow up by using stably transfected cell lines. I expected that this approach would 
allow me to perform a biochemical analysis along with better control of expression 
levels of the respective chimaeras. Moreover, stable transfection would enable me to 
use MDA-MB-231 cells. In collaboration with Dr. Tomas Brdicka we created stably 
transfected A375 and MDA-MB-231 cells lines by retroviral transfer. Briefly, 
retroviruses were prepared by transfection of the cells with DNA plasmids. Upon the 
centrifugation of retroviruses-containing supernatant, the cleared supernatant was used 
to spin-infect A375MM and MDA-MB-231 cells. The infected cells were then FACS- 
sorted to obtain the OFP-positive population (Fig. 4.6).
4.2.6 Membrane domain localization of Csk chimaeras in stably transfected cells
To validate the obtained stably transfected cell lines, I verified the predicted 
localization of each single Csk construct in the specific membrane domains. The 
primary biochemical approach to separate lipid rafts involves the discontinuous high­
speed density gradient equilibrium assay. The unique lipid composition of lipid rafts 
endows them with resistance to solubilisation in non-ionic mild detergents, as opposed 
to the bulk cellular membrane material that is readily dissolved in such conditions. 
Upon separation in the discontinuous high density gradient made up of varying 
concentrations of sucrose or iodixanol (marketed as OptiPrep), the non-solubilised lipid
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raft fraction floats with respect to solubilised and insoluble non-lipid material when 
separated in such gradient assay. To this end, A375MM cells stably expressing the Csk 
chimaeras were lysed in a TNE buffer containing 1% Triton X-100 and subjected to a 
floatation assay on a discontinuous Optiprep gradient. After over-night 
ultracentrifugation, fractions were collected and processed for Western blotting. 
Membranes were probed with antibodies against Myc to detect the Csk chimaeras and 
Caveolin 1 as a bona fide marker of lipid rafts. I observed that clearly only the lipid raft- 
targeted constructs, Lat-Csk and Lat-kinase-dead Csk were found in the gradient 
fraction with highest abundance of Cav-1, thus to be considered bona fide lipid rafts. 
Conversely, non-lipid raft targeted CD25-Csk and cytosolic Csk were only found in the 
lower, i.e. heavier fractions (Fig. 4.7). I repeated the same experiments and obtained 
similar results with stably transfected MDA-MB-231 cells.
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LOCALIZATION: PM
Lipid raft Lat (1-33) Csk (W47A, R107K, E154A) myc OFP
Lipid raft Lat (1-33) Csk (W47A, R107K, E154A) myc OFP
Non-raft CD (1-259) Csk (W47A, R107K, E154A) myc OFP
Cytosolic Csk (W47A, R107K, E154A) myc OFP
Fig. 4.5. Construct scheme and subcellular localization of Csk- 
OFP constructs. Abbreviation: PM, plasma membrane; OFP, 
orange fluorescent protein; the numbers in the constructs denote 
the respective amino acid segments. Colour coding: green- 
membrane anchor, violet-Csk, red-a Myc tag, orange-orange 
fluorescent protein
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Fig. 4.6. FACS analysis of A375MM cells stably over-expressing 
Csk-Myc-OFP chimaeras. Cells were detached and 300.000 cells 
were analyzed by FACS to measure the level of transfection. 
Number of cells was plotted (y) against wavelength (x). (A) control 
cells; (B) Lat-Csk: 57,36% OFP+ cells; (C) CD25-Csk: 70,64% 
OFP+ cells; (D) Lat-Csk kinase dead: 96,88% OFP+ cells; (E) 
cytosolic Csk: 90,04% OFP+ cells.
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Fig. 4.7. Floatation assay in a discontinuous Optiprep gradient.
A375MM cells were lysed in Triton X-100-containing buffer. 
Fractions were collected and subjected, together with initial lysates 
(I) to Western blotting and probed with anti-Myc antibody to stain 
Csk-Myc-OFP chimaeras. Caveolin 1 was used as a bona fide 
marker of lipid rafts. Clearly, only Lat-Csk and Lat-Csk kinase 
dead were detected in the lighter fraction of Optiprep gradient, 
together with Cav 1. CD25-Csk and cytosolic Csk were found in 
the heavier fraction, as expected.
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4.2.7 Effect of Csk compartmentalization on ECM degradation
Finally, having confirmed the proper localization of Csk constructs in the 
discontinuous Optiprep gradient, I evaluated whether the specific membrane 
localization of Csk had any effect on the cells’ ability to degrade the ECM.
I performed the ECM degradation assays as described above. In the A375MM 
cells, the results were similar to those obtained with transient transfection of Csk 
chimaeras, i.e. inhibition of degradation after over-expression of lipid-raft targeted Csk 
(Fig. 4.9 A). In line with the result in A375MM cells, the stably transfected MDA-MB- 
231 displayed similar behaviour. When MDA-MB-231 cells were plated on the 
gelatine, the degradation was significantly lowered in cells stably transfected with lipid- 
raft targeted (Lat-Csk) (Fig. 4.9 B).
4.2.8 Effect of Csk compartmentalization on cell migration
Csk has been shown to play a regulatory role in cell migration. Adenovirus- 
mediated over-expression of wild type Csk attenuates cell motility in colon cancer cell 
lines HCT15 and HT29 (Rengifo-Cam et al., 2013). Gs-linked G protein-coupled 
receptor activation of cAMP-dependent protein kinase (PKA) in endothelial cells 
suppresses cell migration via a Csk-mediated regulation of SFK (Bae and Paik, 1997; 
Jin et al., 2010). Also, as mentioned above, expression of a wt-, but not kinase dead Csk 
disrupted the EGF-induced activation of SFKs and cell migration on vitronectin 
(Ricono et al., 2009). Hence, I followed up on these studies by investigating whether the
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compartmentalization of Csk function in different membrane domains has an effect.
I plated FACS-sorted MDA-MB-231 cells in the culture inserts and allowed 
them to attach overnight. The second day, I removed the inserts and allowed the cells to 
migrate for 16 h. Then, I measured the gap at time 0 and end time. I could clearly 
observe an effect of lipid raft targeted Csk on migration, as compared to different 
controls, including mock, cytosolic Csk and kinase dead lipid raft targeted Csk. Lipid 
raft targeted Csk inhibited migration by 50 per cent, while expression of bulk membrane 
targeted Csk did not affect migration (Fig. 4.9).
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Fig. 4.8. Subcellular localization of Csk-OFP constructs. Stably 
transfected A375MM cells were plated on the FITC-conjugated 
gelatin (green). The following day, cells were fixed and stained 
with anti-Myc antibody to reveal the Csk construct (red). White 
arrow shows the colocalization of lipid raft targeted kinase dead 
Csk (Csk KD) with the degradation site. Scale bar 10 pm.
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Fig. 4.9. ECM degradation after over-expression of Csk 
chimaeras targeted to different membrane domains. Stably 
transfected A375MM (A) and MDA-MB-231 (B) cells were plated 
on the FITC-conjugated gelatin in the presence of BB94 to block 
invadopodia formation. The following day, a degradation assay 
was performed. Only lipid raft targeted Csk (Lat-Csk) was able to 
inhibit ECM degradation. Error bars represent standard deviation 
of the mean. Three independent experiments were performed. P < 
0 .001 .
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Fig. 4.10. Lipid raft-targeted Csk slows down the gap closure in 
wound healing assay. Stably transfected MDA-MB-231 cells were 
plated in the culture inserts prior to the insert removal. Cells were 
observed after 16 h. Error bars represent standard deviation of the 
mean. Three independent experiments were performed. P < 0.001.
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4.3 Discussion
Invadopodia were first indentifled in v-Src fibroblasts and later described as Src 
activation-dependent structures. Invadopodia formation initiates upon Src activation in 
response to inputs such as EGF, PDGF or integrin-mediated adhesion (Destaing et al., 
2011) to promote invasive migration. Src is both necessary and sufficient for 
invadopodia formation, as has been repeatedly demonstrated. Indeed, Src targets a 
number of substrates to orchestrate invadopodia formation, maturation and disassembly 
(reviewed in Boateng and Huttenlocher, 2012) by involvement in different processes: a) 
actin polymerization; b) MT1-MMP endocytosis and c) calpain-mediated proteolysis. 
Hence, full understanding of SFK regulation at invadopodia is of central interest in the 
invadopodia biology.
Although there has been a substantial progress in understanding the molecular 
machinery of invadopodia, surprisingly little is known about regulation of Src activity 
at these structures. Recently, it has been suggested that ROS, such as hydrogen peroxide, 
are generated locally at invadopodia by Tks5-mediated activation of Nox complex and 
that they are indispensible in the initiation of invadopodia formation (Diaz et al., 2009). 
Although direct evidence is still lacking, it is an intriguing possibility that ROS 
modulate Src activity via phosphorylation of cysteine (Cys) residue. In addition, 
phosphatase PTP1B activates Src by dephosphorylation of C-terminal inhibitory 
tyrosine during invadopodia assembly (Cortesio et al., 2008).
In this study, I focused on the negative regulator of Src, C-terminal Src kinase 
(Csk). Csk specifically phosphorylates the N-terminal tyrosine Src to induce 
intramolecular binding and inhibition. I demonstrated the inhibitory action of Csk at
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invadopodia formation using RNA interference. Moreover, I provided evidence that the 
enhanced gelatine degradation per cell after Csk ablation coincided with activation of 
SFK due to decreased phosphorylation of the inhibitory tyrosine of SFK, accompanied 
by higher phosphorylation of SFK substrates. In line with this evidence, only 
catalytically active wild-type Csk efficiently restored the phenotype induced by Csk 
knock-down. Moreover, I showed that the activity of Csk at invadopodia is confined to 
the lipid rafts, as only the lipid rafts targeted wt Csk efficiently blocked invadopodia 
formation and consequent degradation.
These results complement the evidence of invadopodia as lipid raft-rich 
membrane. In the normal cellular context, Csk is delocalized to specific membrane 
compartments by binding to phosphorylated scaffold proteins, such as Cbp/PAG 
(Kawabuchi et al., 2000) or caveolin 1 (Cao et al., 2002). In my laboratory, we have 
previously shown that caveolin 1 phosphorylation on tyrosine 14 acts inhibitory towards 
invadopodia formation, probably due to decrease of plasma membrane cholesterol 
levels and partial contribution of SFK inhibition (Caldieri et al., 2009). It would be 
challenging for the future research to investigate whether axis Csk-Cavl-Src contributes 
to invadopodia regulation, and if so, how the complex is regulated spatiotemporally. 
Although the detection of spatiotemporal changes in Src activity has been difficult due 
to lack of reliable tools, the recent development of new biosensors might help to get 
further insight to Src-dependent signalling events at invadopodia (Gulyani et al., 2011).
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CHAPTER 5: ARF6-mediated trafficking is involved in 
invadopodia formation and function
5.1 Introduction
ARF6 is a small molecular weight GTPase that localizes to the plasma membrane 
and endosomal compartment where it regulates endocytic membrane trafficking and 
actin remodelling (Donaldson, 2009; Grant and Donaldson, 2009). Over the last few 
years, ARF6 GTPase is emerging also as an important regulator of invadopodia 
formation.
Studies investigating the role of ARF6 in melanoma and breast tumour cell 
invasion have shown that endogenous ARF6 localized at invadopodia and that ARF6 
activity is required for invadopodia formation (Tague et al., 2004). These effects, 
together with the well known ability of ARF6 to regulate endosomal membrane 
recycling, may suggest that the ARF6-dependent recycling compartment regulates bulk 
membrane available for the formation of invadopodia (Schweitzer et al., 2011). 
Moreover, ARF6 influences the deposition and distribution of membrane proteins, such 
as a6|31 integrin, which has been shown to be important for the initiation of 
invadopodia (Nakahara et al., 1998).
The ARF6 recycling compartment is organized in long tubules that develop from 
the perinuclear recycling compartment and are generally extended toward the leading 
edge of the cells (Weigert et al., 2004). Such tubules contain many other associated
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proteins such as Rab22, PLD2, PIP5K (Porat-Shliom et al., 2008) and are enriched in 
certain lipids, such as cholesterol and PtdIns(4,5)P2.
In this section, I focused on the constituents and cargo of ARF6-dependent 
pathway. I proved to show that both the constituents and cargo are localized and 
recycled, respectively at invadopodia. Moreover, inhibition of PLD2, a component of 
ARF6 pathway led to decrease in the level of gelatine degradation.
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5.2.1 Constituents of ARF6 pathway are present at invadopodia
I resorted to an immunofluorescence (IF) approach to examine whether the ARF6 
recycling compartment could be connected to the invadopodia sites. ARF6 is the only 
member of the small ARF GTPases to localize at the PM where it regulates membrane 
trafficking through phospholipase D2 (PLD2) and PIP5K, resulting in the generation of 
phosphatidic acid and PIP2.
PLD2 colocalizes with ARF6 at the plasma membrane and on endosomal 
membranes and, more importantly, PLD2 is selectively activated by ARF6 (Hiroyama 
and Exton, 2005). Upon activation, PLD2 catalyzes the hydrolysis of 
phosphatidylcholine (PC) to form choline and phosphatidic acid (PA), a signaling lipid 
that can be further converted to diacylglycerol (DAG) (Porat-Shliom et al., 2008).
ARF6 can interact with, and activate PIP5K in the presence of PA to produce 
PtdIns(4,5)P2 and over-expression of ARF6 increases PtdIns(4,5)P2 levels at the plasma 
membrane (Honda et al., 1999; Martin et al., 1996). Similarly to the over-expression of 
a constitutively active form of ARF6 (Q67L), over-expression of PIP5K induces the 
formation of large internal vesicle structures, probably through the fusion of endocytic 
vesicles that are prevented from recycling back to the plasma membrane (Aikawa and 
Martin, 2005). While PIP5K-induced vesicle formation is not blocked by a dominant- 
negative form of ARF6, PIP5K probably acts downstream of ARF6 to induce CIE.
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In my analysis, cells plated on gelatine were transfected with GPF-tagged variants of 
mentioned proteins and then subjected for IF. The results revealed that all examined 
accessory proteins of the ARF6 recycling pathway, PLD2 (Fig. 5.1), syntaxin 2 (Fig. 
5.2.) and 3 (Fig. 5.3) localize at the actin-rich degradation sites. In addition, I used a 
construct encoding the PH domain of PLC-8 that specifically binds PtdIns(4,5)P2, the 
product of PIP5K (Fig. 5.4).
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Fig. 5.1. PLD2 localization in the actively degrading cells.
A375MM cells transfected with PLD2-GFP were detached, plated 
on fluorophore conjugated gelatine coated coverslips and fixed 
after over night degradation. Colocalization with underlying 
degradation is shown (white arrows). Green: GFP construct, red: 
gelatine, blue: F-actin. Merge image also shown. Three
independent experiments were performed. Scale bar 10 pm.
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Fig. 5.2. Syntaxin 2 localization in the actively degrading cells.
A3 75MM cells transfected with syntaxin 2-GFP were detached, 
plated on fluorophore conjugated gelatine coated coverslips and 
fixed after over night degradation. Green: GFP construct, red: 
gelatine, blue: F-actin. Colocalization with underlying degradation 
is shown (white arrows). Merge image also shown. Three 
independent experiments were performed. Scale bar 10 pm.
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Fig. 5.3. Syntaxin 3 localization in the actively degrading cells.
A375MM cells transfected with PH-PLC-GFP were detached, 
plated on fluorophore conjugated gelatine coated coverslips and 
fixed after over night degradation. Green: GFP construct, red: 
gelatine, blue: F-actin. Colocalization with underlying degradation 
is shown (white arrows). Merge image also shown. Three 
independent experiments were performed. Scale bar 10 pm.
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/Fig. 5.4. PH-PLC localization in the actively degrading cells.
A375MM cells transfected with PH-PLC-GFP were detached, 
plated on fluorophore conjugated gelatine coated coverslips and 
fixed after over night degradation. Green: GFP construct, red: 
gelatine, blue: F-actin. Colocalization with underlying degradation 
is shown (white arrows). Merge image also shown. Three 
independent experiments were performed. Scale bar 10 pm.
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5.2.2 PLD2 inhibition blocks ECM degradation
To follow up on the IF analysis of the ARF6 recycling compartment accessory 
proteins, I chose to examine role of PLD2 in invadopodia-mediated ECM degradation. 
For that, I used a small molecular weight compound, 5-fluoro-2-indolyl des- 
chlorohalopemide (FIPI), which had been identified in an in vitro chemical screen as a 
strong PLD2 inhibitor, consequently blocking the synthesis of the lipid second 
messenger PA (Monovich et al., 2007; Su et al., 2009). Briefly, I performed a 
degradation assay in the presence of 750 nM FIPI for 5 h. Strikingly, ECM degradation 
in cells treated with FIPI was almost completely blocked as compared to control cells 
(Fig. 5.5 A).
Furthermore, I performed loss of function experiments by down-regulating 
PLD2 with siRNA (Fig. 5.5 B), and similarly I observed inhibition of gelatine 
degradation, albeit less striking as compared to the FIPI effect (Fig. 5.5 C).
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Fig. 5.5. PLD2 inhibition leads to a decrease in ECM 
degradation. Quantification of ECM degradation revealed more 
than 50% decrease in degradation per cell in FlPI-treated (FIPI) 
compared to mock (mock)-treated A375MM cells. A) Efficiency 
of PLD2 knock-down. A375MM cells were treated without (mock) 
or with (RNAi) siRNA targeting PLD2 for 96 hours. RNAi reduced 
PLD2 expression up to 85% as shown in western blots of lysates 
using antibodies against PLD2 and actin as a loading control. B) 
Quantification of ECM degradation revealed more than 50 
decrease in degradation per cell in PLD2 knock-down (RNAi) 
compared to mock-transfected (mock) A375MM cells. Error bars 
represent standard deviation of the mean. Three independent 
experiments were performed. P < 0.001.
5.2.3 ARF6-dependent cargo CD147 is delivered to the sites of matrix degradation
As shown above, constituents of ARF6-associated endocytic pathway are 
evidently localized at invadopodia. Thus, I decided to explore the fate of ARF6- 
associated cargo. The list of proteins that enter cells via the ARF6-pathway includes the 
well-characterized cargo MHC I and the recently identified ones CD44, CD98 and 
CD 147 (also known as EMMPRIN or basigin) (Eyster et al., 2009). I chose CD 147 for 
the next analysis, since it has been recently shown to enhance matrix degradation by 
breast cancer cells at invadopodia (Grass et al., 2012). CD147 (also known as emmprin 
or basigin) is a single pass integral membrane protein, which is normally expressed at 
low levels in the most of the tissues, but it is highly upregulated during tissue 
remodeling and tumour progression. CD 147, and its overexpression in the cancer- 
related role is associated with induction of expression of MMPs, such as MMP-1, 
MMP-2, MMP-3, MMP-9 and MMP-11 (Weidle et al., 2010)
First, I performed an IF analysis of actively degrading cells on gelatine by 
staining the cells with antibody against endogenous CD 147. Clearly, CD 147 colocalized 
with actin at the degradation sites (Fig. 5.6).
To explore whether recycling of the plasma membrane pool of CD 147 is 
involved in delivery to invadopodia, I employed an antibody binding and internalization 
assay. In this assay, cells are first incubated with antibody-containing complete medium 
to allow the binding and consequent uptake of the antibody. After incubation, cells are 
washed briefly with an acidic buffer. Through a washing step, the surface pool of 
antibody is removed and thus any further antibody detected at the plasma membrane
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will have derived from recycling, not residual binding. I combined this assay with the 
degradation assay. Briefly, cells plated on gelatine were incubated with the antibody 
against CD 147 at 37 °C in the presence of BB94 for 30 min and then washed with low 
pH buffer. After this acid wash, cells were left to degrade matrix for the indicated time. 
I performed IF analysis, showing that the majority of the internalized anti-CD 147
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Fig. 5.6. CD147 localization in the actively degrading cells.
A375MM cells plated on FITC-gelatine (green) were fixed after 
the 30 min uptake of anti-CD 147 antibody and stained without 
permeabilization (red). Colocalization with underlying degradation 
is shown (white arrows). Three independent experiments were 
performed. Scale bar 10 pm.
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Fig. 5.7. Plasma membrane bound CD147 antibody is recycled 
to degradation sites. The uptake of anti-CD 147 antibody was 
performed on the A3 75MM cells plated on the FITC gelatine- 
coated coverslips in the presence of BB94 at 37 °C for 30 min. The 
non-intemalized antibody was washed out with low pH buffer (acid 
wash) and cells were fixed after 6 h of gelatine degradation. 
Uptake of anti-CD 147 antibody was performed for 6 h on 
A375MM cells plated on fluorophore-conjugated gelatine-coated 
coverslips. Cells were fixed 6 h after acid wash. A) merge; B) 
gelatine; C) CD 147. Three independent experiments were 
performed. Scale bar 10 pm.
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antibody is delivered to invadopodia (Fig. 5.7). This confirms that the plasma 
membrane pool of CD 147 was recycled and preferentially delivered to invadopodia. At 
this point, it is important to mention that the internalization of antibody was performed 
in the presence of BB94, i.e. in the condition when invadopodia are not formed. 
Therefore, the accumulation of CD 147 antibody cannot be an artifact of the assay but 
derives from intracellular recycling.
5.2.4 Effect of Seladinl/DHCR24 inhibition on the ARF6-dependent endocytic 
pathway
Proteins and lipids that reside in lipid rafts seem to be prominently internalised via 
clathrin-independent endocytosis (CIE). The widely studied ARF6-dependent 
trafficking is of a particular interest in the context of CIE as it regulates a wide range of 
events of relevance in tumour biology, including cell migration, adhesion and invasion. 
The ARF6-dependent pathway is mainly responsible for the endocytosis of cell surface 
integral proteins that lack adaptor protein localisation sequences. Among these are the 
major histocompatibility complex class I (MHC I) proteins (Radhakrishna and 
Donaldson, 1997), syndecan 1 (Zimmermann et al., 2005), (31-integrin (Brown et 
all.,2001) and the GPI-anchored protein CD59 (Naslavsky et al., 2004). Following 
internalization, vesicles containing these cargo proteins traffic to the early endosomes, 
where they meet the clathrin-dependent cargo. From there, the cargo is either 
transported via a degradative pathway to the late endosomes and lysosomes or recycled 
back to the plasma membrane (Donaldson et al., 2009). In addition, ARF6-dependent
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endosomal trafficking impacts cholesterol homeostasis and is free cholesterol dependent 
(Schweitzer et al., 2011). Therefore, I wondered whether the inhibition of Seladin 
1/DHCR24, and consequent block of cholesterol biosynthesis, might affect the Arf-6 
dependent pathway and trafficking of cargo.
I based my experiment on the trafficking of MHC I, a well-known ARF6- 
dependent cargo (Radhakrishna and Donaldson, 1997). First, I examined whether the 
uptake of MHC I is affected by Seladin 1/DHCR24 inhibition. A375MM cells were 
plated on uncoated coverslips in the presence of lovastatin and mevalonate. The second 
day, antibody uptake was performed after pre-treatment with inhibitors in medium 
containing dFCS. Briefly, cells were incubated with MHC-I antibody at 37 °C and fixed 
at different time-points. I did not observe any significant difference between the control 
and treated cells. Thus, I decided to use a modified protocol, where the uptake of MHC- 
I antibody is preceded by antibody binding on ice. Uptake itself was performed again at 
37 °C and followed by an acid wash. This wash removes the antibody bound on the cell 
surface, while the route of internalized antibody remains intact. Using this approach I 
observed an impairment of the recycling route, especially striking in the Triparanol- 
treated cells. I also found that most MHC I antibody remains in the early endosomes, as 
confirmed by increased co-localization of MHC I and Early Endosome Autoantigen 1 
(EEA-1), a well-known marker of early endosomes (Fig. 5.8 A). This would suggest 
that the inhibition of DHCR24 causes impairment in the recycling via the ARF6- 
dependent CIE pathway back to the membrane. To confirm the specificity of the 
treatments, I performed a phenotype rescue experiment by replenishing cholesterol as 
described previously. I observed the loss of accumulation of internalized MHC I in the
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early endosomes in both Triparanol- and EC-treated cells (Fig. 5.8 B). Interestingly, I 
also observed an increase in number and location (closer to the plasma membrane) of 
early endosomes in all the cholesterol replenished cells (Fig. 5.8 C). One might suggest 
that this change is due to acute cholesterol overload-connected stimulation of ARF6- 
associated endocytosis. This is a speculation at this stage and would require further 
experiments, such as testing different cholesterol concentrations and/or modifying 
treatment times to observe longer-term effects. Another possibility could be cholesterol 
tracking by using some of its fluorescent analogues, eg. Bodipy-cholesterol.
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Fig. 5.8. Inhibition of Seladin 1/DHCR24 blocks recycling of
MHC I. A375MM cells were plated with lovastatin/mevalonate 
mix (mock) and were treated with 24(S),25-epoxycholesterol (EC) 
or Triparanol or left untreated (mock) 4h prior the uptake of anti- 
MHC-I antibody (A) or cholesterol addition followed by MHC-I- 
ab uptake (B). Cells were fixed 30 min after acid wash and stained 
with anti-EEA-1 (green) and anti-MHC I (red) antibody. Merged 
images are also shown. Scale bar 10 pm. C) Colocalization of 
EEA-1 and MHC-I was quantified using ImageJ software. Error 
bars represent standard deviation of the mean. Two independent 
experiments were performed. P < 0.05.
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5.3 Discussion
Invadopodia are cellular structures that confine different cellular processes, such 
as signalling, cytoskeleton remodelling and proteolysis, at discrete areas of the cell 
surface. A current challenge is to understand how the invadopodia components are 
precisely delivered to discrete sites of matrix degradation. Much of the effort to 
elucidate the trafficking to invadopodia has focused on MT1-MMP. The delivery of 
MT1-MMP to the plasma membrane and its activation likely include many pathways. 
At any given time, at least two pools of MT1-MMP exist within the cell: a) a pool of 
newly synthesized protein in route from Golgi compartment to the PM and b) a second 
pool of PM localized MT1-MMP which is constantly internalized through clathrin- 
dependent and -independent mechanisms (Remade et al., 2003) and eventually routed 
to early and late endosomes before being recycled back to the PM (Frittoli et al., 2010; 
Poincloux et al., 2009). Whether and how the secretory/biosynthetic and endo/exocytic 
pathways are coordinately regulated, is currently unknown.
In my work, I focused on the small GTPase ARF6, an important regulator of 
clathrin-independent endocytosis and actin remodelling. A role of ARF6 at invadopodia 
has previously been indicated. However, a direct demonstration of the involvement of 
the ARF6-associated pathway in invadopodia assembly has been lacking. Here I show 
that typical components of ARF6-associated recycling pathway, including PLD2, 
syntaxin 2 and syntaxin 3, are localized at invadopodia. Furthermore, I show that the 
recently discovered ARF6-pathway cargo, CD 147 (Eyster et al., 2009) is localized at
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invadopodia and is continuously recycled to invadopodia during active degradation. 
CD 147, also known as the extracellular matrix metalloproteinase inducer (EMMPRIN) 
or basigin, is enriched on the surface of tumour cells and stimulates adjacent stromal 
cells to produce several matrix MMPs, including MT1-MMP.
On one hand, the role of ARF6 in recycling of proteins from the cell surface 
might be to modulate the availability of specific proteins that are employed in 
invadopodia initiation and function. Such recycled cargo might include specific 
integrins, CD44 and/or CD 147. Delivery of these protein components of invadopodia 
might in turn affect the activity and delivery of MT1-MMP at invadopodia. On the other 
hand, ARF6-dependent endosomal trafficking may control delivery of bulk membrane, 
wherever it is needed as a building block for various membrane protrusions, as 
documented for the leading edge of migrating cells.
An additional possibility is that recycling of MT1-MMP itself is ARF6- 
dependent. Hence, it would be of particular interest to explore the role of ARF6 
recycling compartment in the recycling of MT1-MMP to the invadopodial membrane, 
and some of the approaches presented in this thesis could be employed together with 
ARF6 knock-down and cytochalasin D treatment.
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CHAPTER 6: Final discussion
Invasive tumour-derived or transformed cells, cultured on a flat extracellular 
matrix substratum, extend specialized proteolytically active plasma membrane 
protrusions. These structures, termed invadopodia, are responsible for the focal 
degradation of the underlying substrate. Invadopodia are subcellular structures 
specialised in the focalised proteolysis of the ECM in vitro. Their formation and 
function requires the simultaneous coordination of different cellular processes, such as 
signalling, membrane traffic and cytoskeleton remodelling, at discrete areas of the cell 
surface. How the localisation and the function of all components required for these 
activities, such as integrins and proteases, are spatially and temporally confined to 
specific cell-ECM contacts is not known.
Although the description of the ultrastructural features of invadopodia is still 
rather incomplete, many recent developments have uncovered a tight structure-function 
relationship that is helping us understand how the many invadopodia components are 
recruited, and ultimately, how ECM degradation is so precisely directed. My PhD 
project has been focused on the working hypothesis that these functional features are 
tightly connected to cholesterol homeostasis at the plasma membrane and might be 
achieved through the polarized delivery of invadopodia components to sites of 
degradation. I manipulated cholesterol levels by inhibition of Seladin 1/DHCR24, an 
enzyme known to catalyze the reduction of the double bond of intermediates of 
cholesterol biosynthesis pathway. More importantly, inhibition of this enzyme has been
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shown to lead to accumulation of desmosterol that differs from cholesterol only by the 
presence of a C24 double bond. Interestingly, desmosterol cannot fully substitute 
cholesterol in lipid rafts. I showed here that the decrease of ECM degradation caused by 
Seladin 1/DHCR24 inhibition could be fully reversed by addition of cholesterol.
Tyrosine phosphorylated Caveolin 1 is inhibitory towards invadopodia 
biogenesis and function in its capacity as a regulator of cholesterol homeostasis at the 
plasma membrane and possible regulation of SFK activity (Caldieri et al., 2009). Indeed, 
the phosphorylated caveolin 1 binds the SH2 domain of the SFK-inhibitory kinase Csk 
(Cao et al., 2004), that inhibits SFK-dependent signalling, which is required for 
invadopodia formation. In accordance, I found that ablation of the SFK-inhibitory 
kinase Csk led to increased invadopodia formation and ECM degradation. To exert its 
inhibitory effect, Csk must localize to cholesterol-rich lipid rafts but not to other 
membrane domains, as indicated by experiments using differentially targeted wild type 
and mutant Csk chimeras in transient and stable transfectants.
Furthermore, I provided evidence of a role for the ARF6-associated clathrin- 
independent endocytic and recycling pathway. The cargo that travels along this pathway 
includes both lipid raft and non-lipid raft proteins but cholesterol homeostasis appears 
to be crucial for the functional endocytosis and recycling. In my work, I showed that 
constituents such as syntaxin 2 and 3, PLD2 and PtdIns(4,5)P2 of the ARF6-associated 
pathway are all localized at degradation sites. Moreover, the recently discovered ARF6- 
pathway cargo CD 147 is recycled to the active invadopodia. Along with the inhibitory 
effect of PLD2 ablation on ECM degradation, this provides proof of the direct 
involvement of ARF6-associated recycling at invadopodia.
158
In aggregate, my work contributes to further understanding of the intertwine of 
signalling and membrane trafficking at invadopodia, and shows the dependence of this 
process for the cholesterol homeostasis at the plasma membrane.
These results are further complemented by another project in my laboratory, 
wherein I actively participated. The evidence that invadopodia are specialized, 
cholesterol-rich membrane domains suggest an existence of apical-like raft-dependent 
trafficking, similar to epithelial cells. The plasma membrane of epithelial cells is 
typically organised into apical and basolateral domains separated by tight junctions, and 
characterised by different lipid and protein composition. Similarly, non-polarised cells 
have an ability to establish a clear segregation between diverse functions, by creating 
membrane compartments characterized by a different molecular composition exposed to 
a different milieu.
We found that glycosylphosphatidylinositol-anchored green fluorescent protein 
(an apical model protein), but not vesicular stomatitis virus G-protein or influenza virus 
hemagglutinin (both basolateral model cargoes), was transported to sites of ECM 
degradation. Also, RNAi-mediated knock-down of proteins known to specifically 
regulate polarised apical transport, such as caveolin 1 and annexin XIIIB or basolateral 
transport in epithelial cells, such as clathrin, demonstrated that the selective inhibition 
of the apical, but not the basolateral, transport route impairs invadopodia formation and 
ECM degradation. Invadopodia thus appear to be apical-like membrane domains, where 
signal transduction and local membrane remodelling events might be temporally and 
spatially confined via selective raft-dependent apical transport routes (Caldieri et al.,
2012).
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CHAPTER 7: Future perspectives
My findings converge on the hypothesis that cholesterol influences the 
metastatic process of the tumoural cells. Intriguingly, the solid tumors were show to be 
highly enriched in cholesterol by Swyer in 40s, who found that the cholesterol content 
almost doubled between the normal prostate and prostatic hyperplasia. Since then, the 
interest in the association of cholesterol and cancer has been resuscitated with a seminal 
observation showing that cholesterol lowering drugs statins might be linked with the 
prostate cancer diagnosis. However, the association between cancer and dietary 
cholesterol is not clear (Hu et al., 2011) and the hypothesis might be valid only for some 
types of cancer, such as prostate and breast.
The potential roles of cholesterol in cellular functions supporting tumourigenesis 
are multiple, including the cellular growth, inflammation, membrane organization and 
steroidogenesis. Indeed, the rapid growth and high metabolic rate of tumour cells has to 
be supported by abundance of the essential building blocks, cholesterol among them. At 
advanced disease stage, the tumour cells are even reported to reduce the circulating 
cholesterol, with low serum cholesterol as an effect of progressing cancer (reviewed in 
Solomon and Freeman, 2011).
Cholesterol is an essential component of cell membranes and in complex with 
membrane glycosphingolipids plays a regulatory role by forming a platforms in 
asymmetric membrane domains, aka lipid rafts (Lingwood and Simons 2010). These
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domains are more ordered relatively to bulk plasma membrane and variably accumulate 
proteins involved in cell signalling (Levental et al. 2010), such that membrane rafts 
become foci for bio-information transduction. Our current understanding of lipid rafts is 
still rather incomplete, such as their actual size and lifetime is under debate (Simons and 
Lingwood, 2011). Lipid rafts are increased (Li et al., 2006) and key in the aberrant 
signalling and adhesion of cancer cells (Staubach and Hanisch, 2011). 
Hypercholesterolemia in mice model lead to accumulation of lipid rafts and consequent 
altered plasma membrane signalling and membrane trafficking, accompanied by 
increased phosphorylation of Akt and increased tumour growth in transgenic prostate 
cancer mice (Oh et al., 2010; Zhuang et al., 2005). Intriquingly, higher tumour 
membrane cholesterol in the lipid rafts may help the neoplastic and cancer stem cells to 
avoid the immunodetection by hindering the glycosphospholipids, too. In the lipid raft 
rich plasma membrane of tumour cells, cholesterol makes glycosphingolipids’ epitopes 
unavailable for active antibody recognition (Novak et al., 2013).
The oxidation and deposition of cholesterol in the atherosclerotic lesions is a 
common pathological consequence of the hypercholesterolemia and it is a common 
cause of inflammatory response that leads to cardiovascular disease. Given that certain 
pool of human cancer is thought to develop as a consequence of inflammation, the role 
of oxidized cholesterol in promoting inflammatory responses could be a factor in 
initiation of carcinogenesis (Pelton et al., 2012).
The abberant tumour cells’ demand for cholesterol is satisfied both by loss of 
feedback regulation, leading to enhanced enhanced cholesterol synthesis and uptake via 
upregulated LDL receptors (Chen and Hughes-Fulford 2001; Hentosh et al., 2001).
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As a vital part of body’s chemistry, cholesterol serves as a precursor of steroid 
hormones; it is then likely that cholesterol promotes the growth of hormone dependent 
tumours by this virtue. Prostate tumor cells respond to androgen through the action of 
the androgen receptor (AR), a nuclear receptor that controls PCa cell proliferation at all 
stages of disease, including late-stage, castration-resistant disease. The xenograft 
prostate cancer tumours express all the enzymes necessary for the de novo synthesis of 
androgens of cholesterol, and the cholesterol levels correlate with expression of 
CYP17A. Thus, cholesterol acts merely not only as an essential precursor, but also as an 
agonist of androgen synthesis. Secondly, cholesterol is a precursor of estrogen, which 
has a clearly established role in the etiology of the breast cancer. The results of recent 
research on the breast cancer imply that increased cholesterol levels help tumour cells to 
feed the tumour with estrogen, leading to the tamoxifen resistance (Nelson et al.,
2013).
Accumulating evidence on the pathological role of invadopodia provides a 
rationale to study them as a possible therapeutical target. They represent excellent 
model structures to study ECM degradation, a key step to in invasion and metastatic 
process, and might provide new avenues into novel anti-cancer therapeutics. My results 
support the idea that the pharmacological alteration of cholesterol biosynthesis, or 
alteration of Csk localization in the cholesterol-rich lipid rafts, or ARF6-associated 
membrane trafficking events regulates the invadopodia biogenesis and function. The 
findings discussed in my thesis suggest a role for cholesterol in proteolytic degradation 
of ECM, deriving from its role in the membrane organization.
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Although the mechanisms of the association of cholesterol and cancer have not 
yet been unequivocally elucilated, it is becoming clear that cholesterol is able to affect 
key attributes of tumour biology. Given the abundance of cholesterol in the Western 
diet, the ability to effectively target this molecule or its metabolism and moderate its 
downstream effectors would be a tremendous advance cancer prevention and treatment. 
One such approach would be to employ enhanced cholesterol lowering drugs as 
adjuvant therapy to conventional therapies. Also other stategies aimed at dysregulated 
cholesterol regulation in cancer cells emerge as a possible avenue to combat the cancer.
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